



ICoLA 2022 with APSAVD | SEP 15-17, 2022 | CONRAD Seoul, Korea

[www.icola.org](http://www.icola.org)

# ICoLA 2022 with APSAVD

The 11<sup>th</sup> International Congress on Lipid & Atherosclerosis  
with Asian-Pacific Society of Atherosclerosis and Vascular Disease

SEP 15<sup>Thu</sup> - 17<sup>Sat</sup>, 2022  
CONRAD Seoul, Korea

The Korean Society of Lipid and Atherosclerosis

Tel: +82-2-3272-5330 Fax: +82-2-3272-5331

E-mail: [ksla@lipid.or.kr](mailto:ksla@lipid.or.kr)

No.707,Mapoacro Tower, 68 Mapo-daero, Mapo-gu,  
Seoul 04168, Korea

Secretariat of ICoLA 2022

Tel: +82-2-2285-2507 Fax: +82-2-3275-3099

E-mail: [secretariat@icola2022.org](mailto:secretariat@icola2022.org)

2F, 204 Wonhyo-ro, Yongsan-gu, Seoul 04368, Korea



“Safe  
and efficient!”

Atorvastatin  
Ezetimibe

안전하고 효과적인 고지혈증 치료제

**Litorvazet** <sup>®</sup> Tab

리토바젯정 [Ezetimibe / Atorvastatin]

10/10, 10/20, 10/40mg



콜레스테롤 합성과 흡수 동시 억제



안전하고 효과적인 LDL-C 감소효과



추가적인 지질개선 효과

# Perfect LDL-C management with Rosuzet



- **Korea's First** Fixed Dose Combination of Rosuvastatin + Ezetimibe<sup>1</sup>
- **World's First** study on CV Outcome\* with Rosuvastatin + Ezetimibe<sup>2</sup>
- **Korea's No.1** in sales of Statin + Ezetimibe Fixed Dose Combination Market<sup>3</sup>
  - **Korea's No.1** most prescribed outpatient medication

**Hanmi** Global · R&D Leader  
**Hanmi Pharm.**

\* **LDL-C:** Low Density Lipoprotein Cholesterol, **CV(Cardiovascular) Outcome:** 3-year composite of cardiovascular death, major cardiovascular events, or non-fatal stroke

**References** 1. Ministry of Food and Drug Safety Integrated Medicine Information System, 2. Kim BK, Hong SJ, Lee YJ, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. *Lancet*. 2022 Jul 30;400(10349):380-390. 3. Cumulative Prescription Data from UBIST in 2021.



# Program at a glance

## Day 1 September 15, Thu

■ Korean 
 ■ English

Floor	3F			5F	6F
Room	1	2	3	4	Poster Hall
11:00~	Registration (5F)				
12:00~12:50	<b>Luncheon Symposium 1</b> [Daewoong]	<b>Luncheon Symposium 2</b> [Chong Kun Dang]			Poster Viewing
12:50~14:20	<b>Symposium 1</b> Optimal risk factor control in patients with DM	<b>Basic Research Workshop 1</b> Lipid metabolism & metabolic disorders	<b>Symposium 2</b> Novel risk factors & intervention targets in atherosclerosis	<b>Symposium 3</b> NAFLD, metabolic dysfunction & ASCVD	
14:20~14:30	Coffee Break				
14:30~15:30		<b>Oral Presentation 1 (APSAVD Young Investigator Session)</b>			
15:30~17:00	<b>Symposium 4</b> Update on coronary CT: risk marker, monitoring tool & future perspective	<b>Basic Research Workshop 2</b> SMC plasticity in plaque stability		<b>Symposium 5</b> Lipid as risk & target in cerebrovascular disease	
17:10~	Welcome Reception (3F, Room 3)				

## Day 2 September 16, Fri

■ Korean 
 ■ English

Floor	3F			5F	6F
Room	1	2	3	4	Poster Hall
07:30~	Registration (5F)				
08:00~09:00	<b>Breakfast Symposium 1</b> [Celltrionpharm]	<b>Breakfast Symposium 2</b> [Organon]			Poster Viewing
09:00~09:40	<b>Plenary Lecture 1</b> From reading the genome for risk to rewriting it for cardiovascular health				
09:40~09:45	Break				
09:45~11:15	<b>Symposium 6</b> Adipose tissue & atherosclerosis	<b>Symposium 7</b> New regulators of dyslipidemia & atherosclerosis	<b>Symposium 8</b> High CV risk group: is it properly defined?	<b>Symposium 9</b> Update on non-pharmacological control of ASCVD risk	
11:15~11:25	Coffee Break				
11:25~11:30	Opening Address (3F, Room 1,2,3)				
11:30~12:00	<b>Plenary Lecture 2 (APSAVD:Ding Lecture)</b> Recent developments in the treatment of familial hypercholesterolaemia & other familial lipid disorders				
12:00~12:50	<b>Luncheon Symposium 3</b> [Organon]	<b>Luncheon Symposium 4</b> [JW Pharmaceutical]	<b>Luncheon Symposium 5</b> [Viartis]	<b>Luncheon Symposium 6</b> [Boehringer Ingelheim / Lilly]	
12:50~12:55	Break				
12:55~13:35	<b>Plenary Lecture 3</b> Senescence & vascular smooth muscle cell plasticity				
13:35~15:05	<b>Symposium 10</b> Debate on developing risk grouping in Korea: current status, comparison with foreign, & solution	<b>Food &amp; Nutrition Workshop</b> Cardiometabolic disease & customized nutrition management	<b>Symposium 11</b> Inflammation in progression & inhibition of atherosclerosis	<b>Symposium 12 (IAS/APSAVD/JAS Joint Symposium)</b> Dyslipidaemia	
15:05~15:15	Coffee Break				
15:15~16:15	<b>Oral Presentation 2</b>	<b>Oral Presentation 3</b>	<b>2022 KSoLA Awards for Scientific Excellence &amp; Young Investigator</b> Scientific Excellence Award Lecture		Moderated Poster 1,2,5 (Kor / Eng)
16:15~17:45	<b>Symposium 13</b> Debate on new Korean guidelines on dyslipidemia: treatment	<b>Publication Committee Session</b>	<b>Symposium 14 (JAS/KSoLA Joint Symposium)</b> Impact of aging of vascular cells on atherosclerosis & its protection	<b>Symposium 15 (APSAVD Joint Symposium)</b> COVID-19 & cardiovascular risk	Poster Viewing
17:55~	Dinner (6F, Studio 1,2,3)				

## Day 3 September 17, Sat

■ Korean 
 ■ English




Floor	3F			5F	6F
Room	1	2	3	4	Poster Hall
07:30~	Registration (5F)				
08:00~09:00	<b>Breakfast Symposium 3</b> [Yuhan]	<b>Breakfast Symposium 4</b> [JW Pharmaceutical]			Poster Viewing
09:00~09:40	<b>Plenary Lecture 4</b> Effect of alirocumab in subjects with likely familial hypercholesterolemia or type III hyperlipidemia: analyses from the ODYSSEY outcomes study				
09:40~09:45	Break				
09:45~11:15	<b>Symposium 16</b> Current issues in severe dyslipidemia	<b>Symposium 17</b> Emerging targets & drug platforms in dyslipidemia & atherosclerosis	<b>Symposium 18</b> Role & unsolved issues of novel lipid-modifying agents	<b>Symposium 19</b> Current nutritional knowledge in cardiometabolic health	
11:15~11:25	Coffee Break				
11:25~12:05	<b>Plenary Lecture 5</b> Best approach to cardio & cerebrovascular health in older people				
12:05~12:55	<b>Luncheon Symposium 7</b> [Inno.N]	<b>Luncheon Symposium 8</b> [Hanmi]	<b>Luncheon Symposium 9</b> [Amgen]	<b>Luncheon Symposium 10</b> [Sanofi]	
12:55~13:00	Break				
13:00~13:30	<b>Plenary Lecture 6 (APSAVD:Yamamoto Lecture)</b> Up close & personal with vascular diseases: the role of precision medicine				
13:30~13:35	Break				
13:35~14:35	<b>Oral Presentation 4</b>	<b>Oral Presentation 5</b>			Moderated Poster 3,4 (Kor / Eng)
14:35~14:45	Coffee Break				
14:45~16:15	<b>Symposium 20</b> How will new technologies change our research & patient care in ASCVD?	<b>Symposium 21</b> New concepts in vascular biology	<b>Symposium 22 (TSLA/KSoLA Joint Symposium)</b> Sex difference in dyslipidemia & atherosclerosis	<b>Symposium 23 (APSAVD Joint Symposium)</b> Update on antibodies & siRNA against PCSK9	Poster Viewing
16:15~	Closing Ceremony (3F, Room 1,2,3)				



The 11<sup>th</sup> International Congress on Lipid & Atherosclerosis  
 with Asian-Pacific Society of Atherosclerosis and Vascular Disease  
 SEP 15<sup>Thu</sup> - 17<sup>Sat</sup> 2022 | CONRAD Seoul, Korea



# Floor Plan



- Room 3 (Grand Ballroom I)**
- Plenary Lectures 1, 2, 3, 4, 5, 6
  - Symposium 2, 8, 11, 14, 18, 22
  - Scientific Excellence Award Lecture
  - Luncheon Symposium 5, 9
  - Opening Address
  - Weclome Reception
  - Closing Ceremony

- Poster Hall (Studio 8, 9, 10)**
- Moderated Poster 1, 3, 5

- Poster Hall 7 (Studio 7)**
- Moderated Poster 2, 4



# COVID-19

## COVID-19 Instructions at ICoLA 2022

---

Anyone who has any symptoms related to COVID-19 is not allowed to attend the ICoLA conference. Please keep your mask on indoors at all times except when eating and drinking. Wash your hands frequently with alcohol-based hand rub or soap and water.

If you are experiencing suspicious symptoms of COVID-19 or have tested 'positive' for COVID-19, please contact us as soon as possible to be able to assist you.

· **Contact number: +82-10-4888-7233**

### When you have symptoms of COVID-19

- Keep a KF94 mask on at all times and avoid any forms of contact with others.
- If you have suspicious symptoms, please stay in your hotel room and let us know to give you further instructions.

### When having tested 'positive' for COVID-19

- Please stay in your hotel room and let us know to give you further instructions.
- You will be notified of further instructions from a public health center about the 7-day self-quarantine policies.
- Self-quarantine is only allowed in government-designated accommodations. You need to select and make reservations on WEHOME, A certified accommodation platform by the Republic of Korea government, for your quarantine.

**\*Please note that this is at attendees' own expense.**

## Dr. Kim Otolaryngology Clinic

---

For those who need to COVID-19, we provide information on our appointed COVID-19 testing hospital near the Conrad Seoul Hotel. Before your visit, please check the operating hours of the hospital for your PCR testing.

### Operating Hours

Weekdays: 09:00-16:00 / Saturday: 09:00-14:30

### Address

4F, 42, Yeouinaru-ro, Yeongdeungpo-gu, Seoul

### Tel

02-780-7582

### Distance

On foot: 11 min. / By car 6 min.







# Contents

---

Program at a Glance	03
Floor Plan	04
COVID-19	05
Welcome Message	08
Organization	09
Plenary Speakers	10
Daily Program	11
Day 1 (Thu, September 15, 2022)	
Day 2 (Fri, September 16, 2022)	
Day 3 (Sat, September 17, 2022)	
Oral Presentation	39
Moderated Poster Presentation	45
Poster Exhibition	53
Other Information	61



## Welcome Message

Dear Colleagues,

On behalf of the organizing committee, we are delighted to invite you to the 11<sup>th</sup> International Congress on Lipid and Atherosclerosis (ICoLA) with Asian-Pacific Society of Atherosclerosis and Vascular Diseases (APSAVD), which will be held at Conrad Seoul, Korea on September 15 to 17, 2022.

ICoLA have been steadily developing with the support of our members since established in 2011. This year, we will gladly hold the upcoming conference together with APSAVD.

The atherosclerotic cardiovascular disease and its risk factors, including dyslipidemia, have remarkably increased in Asia in the past couple of decades. Meanwhile, many dedicated researchers and physicians are working to develop better treatment strategies and novel therapeutic tools for the patients.

ICoLA 2022 will be a premier academic gathering for those involved in the treatment of atherosclerosis and vascular diseases and the research being undertaken to address areas of concern. World-renowned experts have been invited as speakers to share their experiences and provide perspectives on the most recent scientific advances.

Stabilization of the COVID-19 situation in Korea has enabled us to stage this year's congress event on-site. We hope the conference will provide participants with a perspective of current knowledge and facilitate new working networks and collaborations.

On behalf of all members of the ICoLA 2022 organizing committee, we look forward to meeting you in Seoul.

Respectfully yours,



*Myung A Kim*

**Myung A Kim, M.D., Ph.D**

*President  
The Korean Society of Lipid &  
Atherosclerosis (KSoLA)*



*Donghoon Choi*

**Donghoon Choi, M.D., Ph.D**

*Chairman, Board of directors  
The Korean Society of Lipid &  
Atherosclerosis (KSoLA)*

## Organizing Committee

### President

Myung A Kim *Seoul National University*

### Vice-president

Jae Bum Kim *Seoul National University*

### Chairman

Donghoon Choi *Yonsei University*

### Secretary General

Chul Sik Kim *Yonsei University*

### Vice-Secretary General

Kyung-Soo Kim *CHA University*

Sunghwan Suh *Dong-A University*

Heung Yong Jin *Jeonbuk National University*

Hoyoun Won *Chung-Ang University*

Jiwon Hwang *Inje University*

### Treasurer

Soon Jun Hong *Korea University*

### Director, Planning Committee

Dae Jung Kim *Ajou University*

### Director, Scientific Program Committee

Sang-Hak Lee *Yonsei University*

### Director, Publication Committee

Jaetaek Kim *Chung-Ang University*

### Director, Public Relations Committee

In-Kyung Jeong *Kyung Hee University*

### Director, International Liaison Committee

Sung Hee Choi *Seoul National University*

### Director, Insurance and Legislation Committee

Hyun Jae Kang *Seoul National University*

### Director, Education Committee

Byung Jin Kim *Sungkyunkwan University*

### Director, Clinical Practice Guideline Committee

Sang-Hyun Kim *Seoul National University*

### Director, Clinic Research Committee

Sungha Park *Yonsei University*

### Director, Basic Research Committee

Young Mi Park *Ewha Womans University*

### Director, Food and Nutrition Committee

Min-Jeong Shin *Korea University*

### Director without Portfolio

Kee Ho Song *Konkuk University*

Seonghoon Choi *Hallym University*

Ung Kim *Yeungnam University*

Young Joon Hong *Chonnam National University*

### Auditors

Goo Taeg Oh *Ewha Womans University*

Sung Rae Kim *The Catholic University of Korea*

## Scientific Program Committee

### Director

Sang-Hak Lee *Yonsei University*

### Secretary

SungWan Chun *Soonchunhyang University*

Chan Joo Lee *Yonsei University*

### Vice secretary

Seung-Jun Lee *Yonsei University*

### Members

Pil-Ki Min *Yonsei University*

Han-Mo Yang *Seoul National University*

Jang-Hoon Lee *Kyungpook National University*

Chul-Ung Choi *Korea University*

Young Jun Hong *Chonnam National University*

Masahiro Koseki *Osaka University, Japan*

Kyung-Soo Kim *CHA University*

Jeong-Min Kim *Seoul National University*

Sung Hee Choi *Seoul National University*

Yong Sook Kim *Chonnam National University*

Tae-Sik Park *Gachon University*

Hong-Hee Won *Sungkyunkwan University*

Jae-Hoon Choi *Hanyang University*

Kyung-Sun Heo *Chungnam National University*

Hyeon Jeong Lim *Kyung Hee University*

### Advisors

Dong-Eog Kim *Dongguk University*

Sahng Wook Park *Yonsei University*

Young Mi Park *Ewha Womans University*

Chang Yeop Han *University of Washington, USA*

## Plenary Speakers

### September 16(Fri)

---



#### Plenary Lecture 1

Chairperson: Donghoon Choi (Yonsei University, Korea)

#### **From reading the genome for risk to rewriting it for cardiovascular health**

Sekar Kathiresan (*Verve Therapeutics, USA*)



#### Plenary Lecture 2 (APSAVD:Ding Lecture)

Chairperson: Richard O'Brien (University of Melbourne, Australia)

#### **Recent developments in the treatment of familial hypercholesterolaemia & other familial lipid disorders**

Brian Tomlinson (*Macau University of Science & Technology, China*)



#### Plenary Lecture 3

Chairperson: Goo Taeg Oh (Ewha Womans University, Korea)

#### **Senescence & vascular smooth muscle cell plasticity**

Martin Bennett (*University of Cambridge, UK*)

### September 17(Sat)

---



#### Plenary Lecture 4

Chairperson: Joong-Yeol Park (University of Ulsan, Korea)

#### **Effect of alirocumab in subjects with likely familial hypercholesterolemia or type III hyperlipidemia: analyses from the ODYSSEY outcomes study**

Sergio Fazio (*Regeneron Pharmaceuticals, USA*)



#### Plenary Lecture 5

Chairperson: Ki Hoon Han (University of Ulsan, Korea)

#### **Best approach to cardio & cerebrovascular health in older people**

Hidenori Arai (*National Center for Geriatrics & Gerontology, Japan*)



#### Plenary Lecture 6 (APSAVD:Yamamoto Lecture)

Chairperson: Richard O'Brien (University of Melbourne, Australia)

#### **Up close & personal with vascular diseases: the role of precision medicine**

Maria Teresa Abola (*University of Philippines, Philippines*)



## **Daily Program**

Day 1 (September 15, Thu)

Day 2 (September 16, Fri)

Day 3 (September 17, Sat)

## Day 1 Sep. 15 Thu

### Registration

11:00-, Lobby (5F)

### Symposium 1 (Korean)

12:50-14:20, Room 1 (3F)

#### Optimal risk factor control in patients with DM

Chairpersons 우정택 (경희의대), 홍영준 (전남의대)

Panels 강신애 (연세의대), 최익준 (가톨릭의대)

12:50-13:10 How much treatable residual risk do we really have?

구보경 (서울의대)

13:10-13:30 Concept of multiple risk factor control in DM

김현민 (중앙의대)

13:30-13:50 Is there special tool for control of diabetic dyslipidemia?

김남훈 (고려의대)

13:50-14:15 Discussion

### Basic Research Workshop 1

12:50-14:20, Room 2 (3F)

#### Lipid metabolism & metabolic disorders

Chairperson Young Mi Park (Ewha Womans University, Korea)

Panels Hyun Duk Jang (Seoul National University, Korea),  
Kyung-Sun Heo (Chungnam National University, Korea)

12:50-13:10 Cellular lipid trafficking & cholesterol homeostasis

Young Mi Park (Ewha Womans University, Korea)

13:10-13:30 Novel lipid droplet factors in macrophage foam cells 

Mireille Ouimet (University of Ottawa, Canada)

13:30-13:50 Regulation of Hippo signaling by Wnt co-receptor LRP6 (LRL receptor-related protein)

Eek-hoon Jho (University of Seoul, Korea)

13:50-14:15 Discussion

## Symposium 2

12:50-14:20, Room 3 (3F)


### Novel risk factors & intervention targets in atherosclerosis

Chairpersons Moon-Kyu Lee (Eulji University, Korea),

Panels Yoo-wook Kwon (Seoul National University, Korea),  
Jong-Chan Youn (The Catholic University of Korea, Korea)

12:50-13:10 **Biological & clinical influence of air pollution on metabolism & vasculature**  
Seung-Pyo Lee (Seoul National University, Korea)

13:10-13:30 **Role of T cell cholesterol efflux pathways in aging & atherosclerosis**   
Marit Westerterp (University of Groningen, Netherlands)

13:30-13:50 **Circadian rhythm as risk & treatment target in ASCVD**   
Mahmood Hussain (New York University, USA)

13:50-14:15 Discussion

## Symposium 3

12:50-14:20, Room 4 (5F)


### NAFLD, metabolic dysfunction & ASCVD

Chairpersons Youngmi Kim (Kyung Hee University, Korea),  
Byung Wan Lee (Yonsei University, Korea)

Panels Chang-Yeon Kim (Daegu Catholic University, Korea),  
Hyewon Lee (Yonsei University, Korea),  
Eugene Han (Keimyung University, Korea)

12:50-13:10 **MAFLD & risk of cardiovascular disease**  
Yong-ho Lee (Yonsei University, Korea)

13:10-13:30 **The role of mitochondrial enzyme PDK in the pathogenesis of NAFLD & ASCVD**  
Jae-Han Jeon (Kyungpook National University, Korea)


13:30-13:50 **Recent evidence between CVD & NAFLD/NASH in Japan**   
Masahiro Koseki (Osaka University, Japan)

13:50-14:15 Discussion

## Coffee break

14:20-14:30

**Oral Presentation 1 (APSAVD Young Investigator Session)** 14:30-15:30, Room 2 (3F)

- Chairpersons Chul-Ung Choi (Korea University, Korea),  
Edward Janus (University of Melbourne, Australia)
- Panels Jun Sung Moon (Yeungnam University, Korea),  
Sangmo Hong (Hanyang University, Korea)
- 14:30-14:37 A novel molecular diagnostic prototype for detection of pathogenic familial hypercholesterolaemia variants in an Asian population  
Norhidayah Rosman (AIMST University, Malaysia)
- 14:37-14:44 Apolipoprotein CIII deficiency exacerbates diet-induced fatty liver & insulin resistance in knock-out rabbits   
Xiangming Tang (University of Yamanashi, Japan)
- 14:44-14:51 PCSK9 inhibitors exhibit attenuation of biomarkers of endothelial activation & oxidative stress in human coronary artery endothelial cells  
Rahayu Zulkapli (Universiti Teknologi MARA, Malaysia)
- 14:51-14:58 Comparison of on-statin lipid & lipoprotein levels for residual cardiovascular risk prediction in type 2 diabetes  
Ji Yoon Kim (Korea University, Korea)
- 14:58-15:23 Q&A

**Symposium 4 (Korean)** 15:30-17:00, Room 1 (3F)

**Update on coronary CT: risk marker, monitoring tool & future perspective**

- Chairperson 서일(연세의대), 박철영 (성균관대의대)
- Panels 전은주 (서울의대), 최철웅 (고려의대)
- 15:30-15:50 Coronary artery calcium score to predict future CV event  
이은정 (성균관대의대)
- 15:50-16:10 What are unsolved issues in the coronary CT research?  
조익성 (연세의대)
- 16:10-16:30 New markers of coronary CT for future CV event  
차민재 (중앙의대)
- 16:30-16:55 Discussion

## Basic Research Workshop 2 (Korean)

15:30-17:00, Room 2 (3F)

### SMC plasticity in plaque stability

Chairperson 김재룡 (영남대)

Panels 김용숙 (전남의대), 임소연 (가톨릭관동대)

15:30-15:50 Dissecting SMC phenotype modulation through the lens of atherosclerosis-associated transcription factors

Juyong Brian Kim (Stanford University, USA)

15:50-16:10 Targeting SMC phenotypic switching in vascular disease

명창선 (충남대)

16:10-16:30 Regulation of phenotypic plasticity of vascular smooth muscle cells

배순식 (부산대)

16:30-16:55 Discussion

## Symposium 5

15:30-17:00, Room 4 (5F)

### Lipid as risk & target in cerebrovascular disease

Chairpersons Sun U. Kwon (University of Ulsan, Korea),


Sang-Ho Jo (Hallym University, Korea)

Panels Jeong-Min Kim (Seoul National University, Korea),

Hoyoun Won (Chung-Ang University, Korea)

15:30-15:50 Lipid management for patients with non-atherosclerotic stroke

Woo-Keun Seo (Sungkyunkwan University, Korea)

15:50-16:10 Target LDL-C level for patients with cerebrovascular disease 

Kazuo Kitagawa (Tokyo Women's Medical University, Japan)

16:10-16:30 The next step in stroke prevention: beyond lowering LDL cholesterol

Yong-Jae Kim (The Catholic University of Korea, Korea)

16:30-16:55 Discussion

## Welcome Reception

17:10-, Room 3 (3F)



### Luncheon Symposium 1 (Korean)

12:00-12:50, Room 1 (3F)

Sponsored by **Daewoong**

Chairperson 최동훈 (연세의대)

Panels 문재연 (차의대), 문준성 (영남의대)

12:00-12:20 Atorvastatin with ezetimibe combination therapy for very high/high risk groups  
이승표 (서울의대)

12:20-12:30 Discussion

### Luncheon Symposium 2

12:00-12:50, Room 2 (3F)

Sponsored by **Chong Kun Dang**

Chairperson Jaetaek Kim (Chung-Ang University, Korea)

Panels Ji Woong Roh (Yonsei University, Korea),  
Sangmo Hong (Hanyang University, Korea)

12:00-12:20 How to manage cardiovascular health with atorvastation in patients  
Hyungdon Kook (Hanyang University, Korea)

12:20-12:30 Discussion

## Day 2 Sep. 16 Fri

### Registration

07:30- (5F)

### Plenary Lecture 1

09:00-09:40, Room 1,2,3 (3F)

Chairperson Donghoon Choi (Yonsei University, Korea)

09:00-09:40 From reading the genome for risk to rewriting it for cardiovascular health **REC**  
Sekar Kathiresan (Verve Therapeutics, USA)

### Break

09:40-09:45

### Symposium 6 (Korean)

09:45-11:15, Room 1 (3F)

#### Adipose tissue & atherosclerosis

Chairpersons 한진 (인제의대), 노정현 (인제의대)

Panels 김남훈 (고려의대), 전성완 (순천향의대)

09:45-10:05 Novel mechanisms for lipogenesis **REC**  
Gina Lee (University of California Irvine, USA)

10:05-10:25 Local & systemic effect of organ fat deposition  
최성희 (서울의대)

10:25-10:45 Sex-dependent NAD<sup>+</sup> metabolism in the liver & adipose tissue **REC**  
Ji-Young Lee (University of Connecticut, USA)

10:45-11:10 Discussion

## Symposium 7


09:45-11:15, Room 2 (3F)

### New regulators of dyslipidemia & atherosclerosis

**Chairpersons** In Kyeom Kim (Kyungpook National University, Korea),  
Soon Jun Hong (Korea University, Korea)

**Panels** Eun Hee Koh (University of Ulsan, Korea)

09:45-10:05 **Validation of metabolic targets in adipose tissue for ASCVD: focus on the KLF14 locus**  
Mete Civelek (University of Virginia, USA)

10:05-10:25 **Deficiency of myeloid PHD proteins aggravates atherogenesis via macrophage apoptosis & paracrine fibrotic signalling**   
Judith Sluimer (Maastricht University, Netherlands)

10:25-10:45 **Understanding the phenotypic changes of vascular smooth muscle cells during atherosclerosis**  
Jae-Hoon Choi (Hanyang University, Korea)

10:45-11:10 **Discussion**


## Symposium 8

09:45-11:15, Room 3 (3F)

### High CV risk group: is it properly defined?

**Chairpersons** Myung A Kim (Seoul National University, Korea),  
Woo Je Lee (University of Ulsan, Korea)

**Panels** Hack-Lyoung Kim (Seoul National University, Korea),  
Jung-Joon Cha (Korea University, Korea)

09:45-10:05 **What is the role of a polygenic risk score in CV risk assessment?**   
Amit Khera (Verve Therapeutics, USA)

10:05-10:25 **Refinement of CV risk in current very high & high risk groups**  
Hyeon Chang Kim (Yonsei University, Korea)

10:25-10:45 **Risk stratification according to age groups in new prevention guidelines**  
Kwang-il Kim (Seoul National University)

10:45-11:10 **Discussion**


## Symposium 9


09:45-11:15, Room 4 (5F)

### Update on non-pharmacological control of ASCVD risk

Chairpersons Ick Mo Chung (Ewha Womans University, Korea),  
Sung Nim Han (Seoul National University, Korea)

Panels Oh Yoen Kim (Dong-A University, Korea),  
Yeon-Kyung Choi (Kyungpook National University, Korea)

09:45-10:05 Cardiovascular disease & the bone marrow   
Matthias Nahrendorf (Harvard Medical School, USA)

10:05-10:25 The dietary pattern approach to prevent cardiovascular disease. Dietary effects on  
HDL subspecies may contribute benefits   
Frank M. Sacks (Harvard Medical School, USA)

10:25-10:45 Trends in dietary quality & cardiometabolic risks among Korean adults  
Min-Jeong Shin (Korea University, Korea)

10:45-11:10 Discussion

## Coffee Break

11:15-11:25

## Opening Address

11:25-11:30, Room 1,2,3 (3F)

## Plenary Lecture 2 (APSAVD:Ding Lecture)

11:30-12:00, Room 1,2,3 (3F)

Chairperson Richard O'Brien (University of Melbourne, Australia)

11:30-12:00 Recent developments in the treatment of familial hypercholesterolaemia &  
other familial lipid disorders   
Brian Tomlinson (Macau University of Science & Technology, China)

## Break

12:50-12:55

### Plenary Lecture 3

12:55-13:35, Room 1,2,3 (3F)

Chairperson Goo Taeg Oh (Ewha Womans University, Korea)

12:55-13:35 Senescence & vascular smooth muscle cell plasticity   
Martin Bennett (University of Cambridge, UK)

### Symposium 10 (Korean)

13:35-15:05, Room 1 (3F)

#### Debate on developing risk grouping in Korea: current status, comparison with foreign, & solution

Chairpersons 정명호 (전남의대), 김성래 (가톨릭의대)

Panels 김경수 (차의대), 박재형 (고려의대)

13:35-13:55 Current evidence on risk stratifying factors in Koreans  
허지혜 (한림의대)

13:55-14:15 How much different event risk do Koreans have compared to European descendants?  
안성복 (이화여대)

14:15-14:35 How to select of low risk individuals to avoid pharmacotherapy?  
김학령 (서울의대)

14:35-15:00 Discussion

### Food & Nutrition Workshop (Korean)

13:35-15:05, Room 2 (3F)

#### Cardiometabolic disease & customized nutrition management

Chairpersons 이명숙 (성신여대), 정효지 (서울대)

Panels 서준 (순천향의대), 임현정 (경희대)

13:35-13:55 Customized functional food based on big data  
김지영 (서울대)

13:55-14:15 Customized prevention of metabolic disease in Koreans using omics technology  
김민주 (한남대)

14:15-14:35 Healthcare program using digital health device  
김영인 (주식회사 가지랩)

14:35-15:00 Discussion

## Symposium 11

13:35-15:05, Room 3 (3F)

### Inflammation in progression & inhibition of atherosclerosis

Chairpersons Hyo-Soo Kim (Seoul National University, Korea),  
Young-Guen Kwon (Yonsei University, Korea)

Panels Young-Kook Kim (Chonnam National University, Korea),  
Chang Hee Jung (University of Ulsan), Korea)

13:35-13:55 **Macrophage diversity in inflammation & homeostasis**  
Ichiro Manabe (Chiba University, Japan)

13:55-14:15 **Inflammation & hematopoiesis in atherosclerosis**   
Katey Rayner (University of Ottawa, Canada)

14:15-14:35 **Immune cell repertoire & novel therapeutic target of aortic aneurysm**  
Seung-Jun Lee (Yonsei University, Korea)

14:35-15:00 Discussion


## Symposium 12 (IAS/APSVD/JAS Joint Symposium)


13:35-15:05, Room 4 (5F)


### Dyslipidaemia

Chairpersons Jaetaek Kim (Chung-Ang University, Korea),  
Richard O'Brien (University of Melbourne, Australia)

Panels Jae Hyuk Lee (Myongji Hospital, Korea), Seung Jin Han (Ajou University, Korea)

13:35-13:55 **Dyslipidaemia - new treatments for ApoC3 & ANGPTL3**   
Brian Tomlinson (Macau University of Science & Technology, China)

13:55-14:15 **Novel selective PPAR $\alpha$  modulator pemafibrate for dyslipidemia & nonalcoholic fatty liver disease (NAFLD)**   
Shizuya Yamashita (Rinku General Medical Center, Japan)

14:15-14:45 **New treatment targets beyond LDL-C in dyslipidaemias**   
Alberico L. Catapano (University of Milan, Italy)

14:45-15:05 Discussion

## Coffee Break

15:15-16:15

## Oral Presentation 2 (Korean)

15:15-16:15, Room 1 (3F)

Chairperson 권유욱 (서울의대)

Panels 조아현 (가톨릭의대), 홍준화 (울지의대)

15:15-15:22 Prediction of future vascular events from thrombus analysis of Ischemic myopathy (TAOISM)

김정민 (서울의대)

15:22-15:29 Comparison of single-pill combination of moderate-intensity rosuvastatin & ezetimibe versus high-intensity rosuvastatin in atherosclerotic cardiovascular disease patients with type 2 diabetes

최효인 (성균관의대)

15:29-15:36 Protocatechuic acid prevents heart failure in isoproterenol-infused mice by downregulating Kmo

기해진 (전남의대)

15:36-15:43 Rh1 ginsenoside suppressed lipopolysaccharide-induced endothelial cell inflammation & apoptosis by inhibiting endoplasmic reticulum stress & TLR4-mediated STAT3/NF- $\kappa$ B pathway

진유진 (충남대)

15:43-16:08 Q&A

## Oral Presentation 3

15:15-16:15, Room 2 (3F)

Chairpersons Hyuk-Sang Kwon (The Catholic University of Korea, Korea),  
Sungha Park (Yonsei University, Korea)


Panels Hyun Min Kim (Chung-Ang University, Korea), Su Jin Jeong (Sejong General Hospital, Korea)

15:15-15:22 Cardiovascular risk factor profiles of familial hypercholesterolaemia patients with & without pathogenic FH candidate gene variants in the Malaysian community

Aimi Zafira Razman (Universiti Teknologi MARA, Malaysia)

15:22-15:29 Impact of genetic testing on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia (GenTLe-FH): a randomized waiting list controlled open-label trial

Akihiro Nomura (Kanazawa University, Japan)

15:29-15:36 Dyslipidemia & type 2 diabetes among Filipino adults 

Cherry Ann Durante (Emilio Aguinaldo College Manila, Philippines)

15:36-15:43 The relationship between total cholesterol level & oxidative stress in the liver tissue of the hyperlipidemic rat model after the intervention with synbiotic beverage

Rafik Prabowo (Universitas Islam Indonesia, Indonesia)

15:43-15:50 Determination of pathogenicity in ABCG5 & ABCG8 gene among Japanese dyslipidemic patients

Nobuko Kojima (Kanazawa University, Japan)

15:50-16:15 Q&A

## Moderated Poster Presentation 1 (Korean)

15:15-15:55, Poster Hall (6F)

Chairperson 김소현 (인하의대)

Panels 김성애 (한림의대), 이재혁 (명지병원)

15:15-15:23 Oas1 deficiency promotes eNOS mRNA degradation, accelerating endothelial dysfunction & atherogenesis

김태경 (이화여대)

15:23-15:31 Loss of myeloid-PCSK9 improves cardio-protection against acute myocardial infarction

문신혜 (이화여대)

15:31-15:39 Peroxiredoxin 3 preserves cardiac function by regulating mitochondrial quality control

손성근 (이화여대)

15:39-15:47 HMGB1 mediates MCP-1 expression in mechanically stressed vascular smooth muscle cells

김지원 (부산대)

## Moderated Poster Presentation 2

15:15-15:55, Poster Hall (6F)

Chairperson Ung Kim (Yeungnam University, Korea)

Panels Yong Sook Kim (Chonnam National University, Korea),  
Heung Yong Jin (Jeonbuk National University, Korea)

15:15-15:23 Cr6 interacting factor 1 deficiency increases homocysteine production in vascular endothelial cells

Cuk Seong Kim (Chungnam National University, Korea)

15:23-15:31 17  $\beta$ -Estradiol Increases APE1/Ref-1 Secretion in vascular endothelial cells : involvement of calcium-dependent exosome pathway

Yu Ran Lee (Chungnam National University, Korea)

15:31-15:39 PFKFB3 & its role on ECM dependent vascular inflammation

Jenita Immanuel (Inje University, Korea)

15:39-15:47 PCSK9 deficient heart-derived ANP promotes cardiac survival after myocardial infarction

Na Hyeon Yoon (Ewha Womans University, Korea)



**Moderated Poster Presentation 5**  
**(APSAVD Young Investigator)**

15:15-15:55, Poster Hall (6F)

- MP5-01** Fenofibrate lowers cardiac lipid accumulation & attenuates diabetic cardiomyopathy in db/db mice  
Jiwon Park (GIST, Korea)
- MP5-02** In vitro & in silico inhibition of IL-6 & NF- $\kappa$ B by *Nigella sativa* oil & thymoquinone as potential anti atherogenic agent  
Al aina Yuhainis Firus Khan (Universiti Teknologi MARA, Malaysia)
- MP5-03** Coronary risk factor profile amongst premature coronary artery disease patients according to different age categories  
Sukma Azureen Nazli (Universiti Teknologi MARA, Malaysia)
- MP5-04** Genetic variations of ABCG5 & ABCG8 genes among clinically diagnosed fh patients attending primary care clinics in Malaysia  
Yung An Chua (Universiti Teknologi MARA, Malaysia)
- MP5-05** Genetic landscape of pathogenic variants in familial hypercholesterolaemia candidate genes among patients attending primary care clinics in Malaysia  
Nur Syahirah Shahuri (Universiti Teknologi MARA, Malaysia)
- MP5-06** Prediction rate of pathogenic variants diagnosed by various diagnostic criteria among familial hypercholesterolaemic patients attending primary care clinics  
Sukma Azureen Nazli (Universiti Teknologi MARA, Malaysia)
- MP5-07** Pharmacologic activation of angiotensin-converting enzyme II alleviates diabetic cardiomyopathy in db/db mice by reducing reactive oxidative stress  
Woo ju Jeong (GIST, Korea)
- MP5-08** Body type parameters predict cerebral small vessel disease  
Ki-Woong Nam (Seoul National University, Korea)
- MP5-09** A comparison of statin treatment algorithms for primary prevention in statin-naive Filipino patients  
Bayani Pocholo Maglinte (Cebu Velez General Hospital, the Philippines)

**2022 KSoLA Awards for Scientific Excellence & Young Investigator Scientific Excellence Award Lecture** 15:15-16:15, Room 3 (3F)

---

Chairpersons Myung A Kim (Seoul National University, Korea),  
Donghoon Choi (Yonsei University, Korea)

15:15-15:20 2022 KSoLA Awards Ceremony for Scientific Excellence & Young Investigator

15:20-15:40 TG lowering: hope vs. hype?  
Sang-Ho Jo (Hallym University, Korea)

15:40-15:45 Q&A

**Symposium 13 (Korean)** 16:15-17:45, Room 1 (3F)

---

**Debate on new Korean guidelines on dyslipidemia: treatment**

Chairpersons 김치정 (중앙의대), 장학철 (서울의대)

Panels 김병진 (성균관의대), 정인경 (경희의대)

16:15-16:35 Korean evidence on target LDL-C levels  
문민경 (서울의대)

16:35-16:55 Are current Western LDL-C targets for each risk groups cost-effective in Koreans?  
김상현 (서울의대)

16:55-17:15 When is clinically appropriate to start anti-PCSK9 Abs?  
남창욱 (계명대)

17:15-17:40 Discussion

## Publication Committee Symposium (Korean)

16:15-17:45, Room 2 (3F)

Chairpersons 박용식 (경희대), 김정민 (서울의대)


16:15-16:20 JLA Award Ceremony

16:20-16:35 Regulation of macrophage activation & differentiation in atherosclerosis  
박성호 (유니스트)

16:35-16:50 Prospect of artificial intelligence based on electronic medical records  
김현성 (가톨릭의대)

16:50-17:05 Intravital two-photon imaging of dynamic alteration of lipid droplet in a live animal model  
김필한 (카이스트)

17:05-17:20 Statin therapy & the risk of osteoporotic fractures in patients with metabolic syndrome: a nested case-control study  
김경진 (고려의대)

17:20-17:35 Metabolism & health impacts of dietary sugars   
Cholsoo Jang (University of California Irvine, USA)

17:35-17:45 Q&A

## Symposium 14 (JAS/KSoLA Joint Symposium)


16:15-17:45, Room 3 (3F)


### Impact of aging of vascular cells on atherosclerosis & its protection

Chairperson Sang Hong Baek (The Catholic University of Korea, Korea)

Panels Kwang-il Kim (Seoul National University, Korea),  
Kyu-Tae Kim (Ajou University, Korea)

16:15-16:35 Aging as risk factor & therapeutic target in atherosclerosis  
Sungha Park (Yonsei University, Korea)

16:35-16:55 Targeting senescent cells as a novel therapeutic strategy for lifestyle-related disease   
Tohru Minamino (Juntendo University, Japan)

16:55-17:15 What effect do cardiovascular medications & diet have on vascular aging?   
Kenichi Tsujita (Kumamoto University, Japan)

17:15-17:40 Discussion

## Symposium 15 (APSAVD Joint Symposium)

16:15-17:45, Room 4 (5F)

### COVID-19 & cardiovascular risk

Chairpersons Young-Bae Park (Seoul National University, Korea),  
Edward Janus (University of Melbourne, Australia)

Panels Hong Nyun Kim (Kyungpook National University, Korea), Jung Ho Heo (Kosin University, Korea)

16:15-16:35 **Impact of risk factors & medications on COVID-19 outcomes**  
In Sook Kang (Ewha Womans University, Korea)

16:35-16:55 **Effect of COVID-19 on dyslipidemia & vascular disease**  
Edward Janus (University of Melbourne, Australia)

16:55-17:15 **Benefit & harm of COVID-19 vaccines in ASCVD**   
Ta-Chen Su (National Taiwan University, Taiwan)

17:15-17:45 Discussion

## Dinner

17:55-, Studio1,2,3 (6F)

## Breakfast Symposium 1 (Korean)

08:00-09:00, Room 1 (3F)

Sponsored by **Celltrionpharm**

Chairperson 이우제 (울산의대)

Panels 서지아 (고려의대), 장지용 (일산병원)

08:00-08:20 **Pioglitazone & cardiovascular risk reduction**  
노정현 (인제의대)

08:20-08:30 Discussion

## Breakfast Symposium 2

08:00-09:00, Room 2 (3F)

Sponsored by **Organon**

Chairperson Seonghoon Choi (Hallym University, Korea)

Panels Bo Kyung Koo (Seoul National University, Korea),  
Hyemooon Chung (Kyung Hee University, Korea)

08:00-08:20 **Management of uric acid in hypertensive patients: role of losartan**  
Hack-Lyoung Kim (Seoul National University, Korea)

08:20-08:30 Discussion

### Luncheon Symposium 3 (Korean)

12:00-12:50, Room 1 (3F)

Sponsored by **Organon**

Chairperson 이홍규 (서울의대)

Panels 윤혁준 (계명대의대), 한승진 (아주의대)

12:00-12:20 Recent update on combination therapy for high risk ASCVD patients  
윤종찬 (가톨릭의대)

12:20-12:30 Discussion

### Luncheon Symposium 4

12:00-12:50, Room 2 (3F)

Sponsored by **JW Pharmaceutical**

Chairperson Jeong Euy Park (Sunkyunkwon University, Korea)

Panels Bong-Ki Lee (Kangwon National University, Korea), Suk Chon (Kyung Hee University, Korea)

12:00-12:20 Cutting edge care of pitavastatin with ezetimibe combination therapy  
Jun Hwa Hong (Eulji University, Korea)

12:20-12:30 Discussion

### Luncheon Symposium 5

12:00-12:50, Room 3 (3F)

Sponsored by **Viatris**

Chairperson Hyun Ho Shin (Asan Chungmu Hospital, Korea)

Panels Jae-seung Yun (The Catholic University of Korea, Korea), Jun Won Lee (Yonsei University, Korea)

12:00-12:20 What are the optimal treatment options of dyslipidemia management for your patients? based on LDL-C lowering continuum  
So-Yeon Choi (Ajou University, Korea)

12:20-12:30 Discussion

### Luncheon Symposium 6

12:00-12:50, Room 4 (5F)

Sponsored by **Boehringer Ingelheim / Lilly**

Chairperson Shung Chull Chae (Kyungpook National University, Korea)

Panels Hye-Mi Kim (Chung-Ang University, Korea), Yeoree Yang (The Catholic University of Korea, Korea)

12:00-12:20 How does empagliflozin connect to CRM : HF underappreciated complication of T2D  
Sang-Hun Shin (Ewha Womans University, Korea)

12:20-12:30 Discussion

## Day 3 Sep. 17 Sat

### Registration

07:30- (5F)

### Plenary Lecture 4

09:00-09:40, Room 1,2,3 (3F)

Chairperson Joong-Yeol Park (University of Ulsan, Korea)

- 09:00-09:40 Effect of alirocumab in subjects with likely familial hypercholesterolemia or type III hyperlipidemia: analyses from the ODYSSEY outcomes study  
Sergio Fazio (Regeneron Pharmaceuticals, USA)

### Break

09:40-09:45


### Symposium 16 (Korean)

09:45-11:15, Room 1 (3F)

#### Current issues in severe dyslipidemia

Chairpersons 최경목 (고려의대), 강현재 (서울의대)

Panels 광수현 (서울의대), 변영섭 (인제의대)

- 09:45-10:05 What is currently best & changing in treatment of adults with FH?  
이원재 (서울의대)
- 10:05-10:25 Update on familial vs multifactorial chylomicronemia syndrome (CS)  
진흥용 (전북의대)
- 10:25-10:45 Understanding role of ANGPTL3 & neighbor molecules   
박훈준 (가톨릭의대)
- 10:45-11:10 Discussion

## Symposium 17

09:45-11:15, Room 2 (3F)

### Emerging targets & drug platforms in dyslipidemia & atherosclerosis

Chairpersons Kyong Soo Park (Seoul National University, Korea),  
Alan Remaley (National Institute of Health, USA)

Panels Gyuri Kim (Sunkyunkwan University, Korea),  
Chang-Hoon Woo (Yeungnam University, Korea)

09:45-10:05 **Impact of lipases on human dyslipidemia & atherosclerosis**  
Hayato Tada (Kanazawa University, Japan)

10:05-10:25 **Discover of new genes involved in low-density lipoprotein metabolism  
by genome-wide CRISPR-Cas9 screens**  
Alan Remaley (National Institutes of Health, USA)

10:25-10:45 **Development of a GalNAc-asiRNA for treatment of NASH with fibrosis**  
Dong Ki Lee (Olix Pharmaceuticals, Korea)

10:45-11:10 **Discussion**


## Symposium 18


09:45-11:15, Room 3 (3F)

### Role & unsolved issues of novel lipid-modifying agents

Chairpersons Byung Jin Kim (Sungkyunkwan University, Korea),  
Soo Lim (Seoul National University, Korea)

Panels Min Kyong Moon (Seoul National University, Korea),  
Jang Hoon Lee (Kyungpook National University, Korea)

09:45-10:05 **Challenges & perspective of drugs for Lp(a)**   
Gisette Reyes-Soffer (Columbia University, USA)

10:05-10:25 **For whom & how much will bempedoic acid work?**   
Raul Santos (University of São Paulo, Brazil)

10:25-10:45 **Recent trial results of new drugs targeting TG rich lipoprotein**  
Eun Ho Choo (The Catholic University of Korea, Korea)

10:45-11:10 **Discussion**


## Symposium 19

09:45-11:15, Room 4 (5F)

### Current nutritional knowledge in cardiometabolic health

Chairpersons Kee Ho Song (Konkuk University, Korea)

Panels In-Jeong Cho (Ewha Womans University, Korea),  
Jeong-Hwa Choi (Keimyung University, Korea)

09:45-10:05 **Organ crosstalk under atherogenic diet**   
Cholsoo Jang (University of California Irvine, USA)

10:05-10:25 **Emerging role of epigenetic regulation by nutrients in inflammation & atherosclerosis**  
Hyunju Kang (Keimyung University, Korea)

10:25-10:45 **Transition to metabolically unhealthy status & cardiometabolic risks**  
Clara Yongjoo Park (Chonnam National University, Korea)

10:45-11:10 Discussion


## Coffee Break

11:15-11:25

## Plenary Lecture 5

11:25-12:05, Room 1,2,3 (3F)

Chairperson Ki Hoon Han (University of Ulsan, Korea)

11:25-12:05 **Best approach to cardio & cerebrovascular health in older people**   
Hidenori Arai (National Center for Geriatrics & Gerontology, Japan)


## Coffee Break

12:50-12:55

## Plenary Lecture 6 (APSAVD:Yamamoto Lecture)

13:00-13:30, Room 1,2,3 (3F)

Chairperson Richard O'Brien (University of Melbourne, Australia)

13:00-13:30 **Up close & personal with vascular diseases: the role of precision medicine**   
Maria Teresa Abola (University of Philippines, Philippines)



**Oral Presentation 4 (Korean)**

13:35-14:35, Room 1 (3F)

Chairperson 허경선 (충남대)

Panels 박세은 (성균관대의대), 서미혜 (순천향의대)

13:35-13:42 Evaluation of the paradoxical association between lipid levels & incident atrial fibrillation according to statin usage: a nationwide cohort study

안효정 (서울의대)

13:42-13:49 Comparison of cerebro-cardiovascular prognosis between cholesterol exposure estimate & cholesterol variability

주형준 (고려의대)

13:49-13:56 Early change in glucose level & risk of new-onset diabetes in patients initiating statin treatment

김충기 (이화의대)

13:56-14:03 Low-density lipoprotein cholesterol level, statin use & myocardial infarction risk in young adults

김미경 (가톨릭의대)

14:03-14:28 Q&A

**Oral Presentation 5**

13:35-14:35, Room 2 (3F)

Chairperson Eun Seok Kang (Yonsei University, Korea)

Panels Yong-ho Lee (Yonsei University, Korea)

13:35-13:42 Ginsenoside Rh1 abolishes ROS-dependent KLF4 signaling pathway to inhibit proliferation & migration of vascular smooth muscle cells

Diem Thi Ngoc Huynh (Chungnam National University, Korea)

13:42-13:49 PCSK9 inhibitors inhibit monocyte adherence to stimulated human coronary artery endothelial cells

Rahayu Zulkapli (Universiti Teknologi MARA, Malaysia)

13:49-13:56 Lipoprotein(a) & cardiovascular & all-cause mortality in Korean adults

Byung Jin Kim (Sungkyunkwan University, Korea)

13:56-14:03 Saffron: a potential natural alternative remedy for statin intolerance

Iman Nabilah Abd Rahim (Universiti Teknologi MARA, Malaysia)

14:03-14:28 Q&A

### Moderated Poster Presentation 3 (Korean)

13:35-14:15, Poster Hall (6F)

Chairperson 전성완 (순천향의대)

Panels 김경수 (차의대), 최한석 (동국의대)

13:35-13:43 Autocrine regulation of cellular migration by secreted molecules from mechanically stressed vascular smooth muscle cells

김주연 (부산대)

13:43-13:51 Depression & subclinical coronary atherosclerosis in adults without clinical coronary artery disease

박경민 (울산대)

13:51-13:59 Effect of lifestyle modification on the improvement of obesity, metabolic parameters & adipo-myokine related risk in overweight/obese adults

하미리 (동아대)

### Moderated Poster Presentation 4

13:35-14:15, Poster Hall (6F)

Chairperson Kae Won Cho (Soonchunhyang University, Korea)

Panels Hoyoun Won (Chung-Ang University, Korea)

13:35-13:43 Mutation in CytB gene associated with macrophage intracellular lipid metabolism  
Vasily Sukhorukov (Institute for Atherosclerosis Research, Russia)

13:43-13:51 Human milk oligosaccharides attenuate lipopolysaccharide-induced endothelial hyper-permeability & migration

Dung Van Nguyen (Chungnam National University, Korea)

13:49-13:59 Modeling of low-density lipoprotein desialylation processes in mice

Dmitry Kashirskikh (Petrovsky National Research Centre of Surgery, Russia)

13:59-14:07 Tyrosine Residues of mitochondrial creatine kinase mitigate hypoxia/reoxygenation injury in the heart through phosphorylation

Maria Victoria Faith Garcia (Cardiovascular and Metabolic Disease Center, Korea)

## Coffee Break

14:35-14:45

## Symposium 20 (Korean)

14:45-16:15, Room 1 (3F)


### How will new technologies change our research & patient care in ASCVD?

Chairpersons 한승환 (가천의대), 김대중 (아주의대)

Panels 이준원(연세의대), 주형준(고려의대)

14:45-15:05 Tips for performing nationwide big cohort studies  
양필성 (차의대)

15:05-15:25 Advance of AI utility in past 5 years in ASCVD care: overview  
조준환 (중앙의대)

15:25-15:45 Novel electrocardiogram generating technique using artificial intelligence: from  
2-lead to 12-lead   
이학승 (메디컬에이아이)

15:45-16:10 Discussion

## Symposium 21 (Korean)

14:45-16:15, Room 2 (3F)

### New concepts in vascular biology

Chairpersons 김치대 (부산대), 국현 (전남대)

Panels 진은선 (경희의대), 허진 (부산대)

14:45-15:05 What's the role of mitochondrial dysfunction in pathogenesis of vascular calcification?  
이인규 (경북의대)

15:05-15:25 Senotherapeutics; a novel strategy for atherosclerosis  
김재룡 (영남대)

15:25-15:45 Extracellular vesicles in endothelial cells: from inter-cellular communication to cargo  
delivery tools  
권기환 (이화의대)

15:45-16:10 Discussion

## Symposium 22 (TSLA/KSoLA Joint Symposium)

14:45-16:15, Room 3 (3F)


### Sex difference in dyslipidemia & atherosclerosis

Chairpersons Sang-Hyun Kim (Seoul National University, Korea), Chul Sik Kim (Yonsei University, Korea)


Panels Sung-Eun Kim (Hallym University, Korea), Sang Min Park (Eulji University, Korea)

14:45-15:05 Characteristics of dyslipidemia & ASCVD of women

Mi-Na Kim (Korea University, Korea)

15:05-15:25 Sex difference in diagnosis & treatment of ASCVD: what do we need to improve in women? 

Ping-Yen Liu (National Cheng Kung University, Taiwan)

15:25-15:45 Is there difference of response to lipid-lowering therapy in women? 

Chih-Fan Yeh (National Taiwan University, Taiwan)

15:45-16:10 Discussion

## Symposium 23 (APSAVD Joint Symposium)

14:45-16:15, Room 4 (5F)

### Update on antibodies & siRNA against PCSK9

Chairpersons In-Kyung Jeong (Kyung Hee University, Korea),  
Hapizah Mohd Nawawi (Universiti Teknologi MARA, Malaysia)

Panels HyunJae Kang (Seoul National University, Korea),  
Jong-Young Lee (Sungkyunkwan University, Korea)

14:45-15:05 Practical approach of PCSK9 Ab use in primary & secondary prevention

Young Joon Hong (Chonnam National University, Korea)

15:05-15:25 Comparison of two drug platforms for PCSK9 inhibition (Monoclonal antibodies & siRNA)

Richard O'Brien (University of Melbourne, Australia)

15:25-15:45 Patients who are resistant to or hypo-respond to PCSK9 inhibitors – a therapeutic challenge

Edward Janus (University of Melbourne, Australia)

15:45-16:15 Discussion

## Closing Ceremony

16:15-, Room 1,2,3 (3F)

### Breakfast Symposium 3 (Korean)

08:00-09:00, Room 1 (3F)

Sponsored by **Yuhan**

Chairperson 손태서 (가톨릭의대)

Panels 김정수 (부산의대), 전성완 (순천향의대)

08:00-08:20 A new paradigm of combination therapy in hypercholesterolemia treatment:  
rosuvastatin & ezetimibe

김병진 (성균관의대)

08:20-08:30 Discussion

### Breakfast Symposium 4

08:00-09:00, Room 2 (3F)

Sponsored by **JW Pharmaceutical**

Chairperson Ung Kim (Yeungnam University, Korea)

Panels Kyung-Soo Kim (CHA University, Korea), Jae Hyuk Choi (Hallym University, Korea)

08:00-08:20 Management of poorly controlled patients with diabetes mellitus

Yong-ho Lee (Yonsei University, Korea)

08:20-08:30 Discussion

### Luncheon Symposium 7 (Korean)

12:05-12:55, Room 1 (3F)

Sponsored by **Inno.N**

Chairperson 이현철 (연세이현철내과)

Panels 박형복 (가톨릭관동대), 서미혜 (순천향의대)

12:05-12:25 Treatment of dyslipidemia with rosuvastatin & ezetimibe

김상현 (서울의대)

12:25-12:35 Discussion


## Luncheon Symposium 8 (Korean)

12:05-12:55, Room 2 (3F)

Sponsored by **Hanmi**

Chairperson 서홍석 (원광대)

Panels 김병규 (인제의대), 조윤경 (울산의대)

12:05-12:25 Why should we consider rosuvastatin-ezetimibe fixed dose combination?: strategies for reaching LDL goals in cardiovascular disease patients   
나승운 (고려의대)

12:25-12:35 Discussion

## Luncheon Symposium 9

12:05-12:55, Room 3 (3F)

Sponsored by **Amgen**

Chairperson Kyong Soo Park (Seoul National University, Korea)

Panels Eu Jeong Ku (Chungbuk National University, Korea),  
Choongki Kim (Ewha Womans University, Korea)

12:05-12:25 Key updates in the recent guidelines – identifying patients for evolocumab therapy  
Wonjae Lee (Seoul National University, Korea)

12:25-12:35 Discussion

## Luncheon Symposium 10

12:05-12:55, Room 4 (5F)

Sponsored by **Sanofi**

Chairperson In-Kyu Lee (Kyungpook National University, Korea)

Panels Jae Hyun Bae (Korea University, Korea),  
Sang-Hun Shin (Ewha Womans University, Korea)

12:05-12:25 The time for intensive lipid lowering therapy in very high-risk patients based on the updated Korean guideline  
Hoyoun Won (Chung-Ang University, Korea)

12:25-12:35 Discussion





# Oral Presentation

The 11<sup>th</sup> International Congress on Lipid & Atherosclerosis  
with Asian-Pacific Society of Atherosclerosis and Vascular Disease



## Oral Presentation

### Oral Presentation 1 (APSAVD Young Investigator Session)

---

Day 1 (Sep. 15\_Thu) 14:30-15:30, Room 2 (3F)

Chairpersons Chul-Ung Choi (Korea University, Korea),  
Edward Janus (University of Melbourne, Australia)

Panels Jun Sung Moon (Yeungnam University, Korea),  
Sangmo Hong (Hanyang University, Korea)

OP1-01 **A novel molecular diagnostic prototype for detection of pathogenic familial hypercholesterolaemia variants in an Asian population**

Norhidayah Rosman<sup>1,2</sup>, Ang Lim Chua<sup>3\*</sup>, Hapizah Mohd Nawawi<sup>2,3</sup>, Alyaa Al-Khateeb<sup>2,3</sup>, Yung An Chua<sup>2,3</sup>

<sup>1</sup>Unit of Pathology, AIMST University, Malaysia

<sup>2</sup>Faculty of Medicine, Institute of Pathology Laboratory and Forensic Medicine IPPerForM, Universiti Teknologi MARA, Malaysia

<sup>3</sup>Faculty of Medicine, Universiti Teknologi MARA, Malaysia

OP1-02 **Apolipoprotein CIII deficiency exacerbates diet-induced fatty liver & insulin resistance in knock-out rabbits**

Xiangming Tang<sup>1</sup>, Jianglin Fan<sup>1\*</sup>, Huanjin Zhou<sup>1</sup>, Haizhao Yan<sup>1</sup>, Manabu Niimi<sup>1</sup>

<sup>1</sup>Basic Science, University of Yamanashi, Japan

OP1-03 **PCSK9 inhibitors exhibit attenuation of biomarkers of endothelial activation & oxidative stress in human coronary artery endothelial cells**

Rahayu Zulkapli<sup>1,2,3</sup>, Hapizah Nawawi<sup>1,2\*</sup>, Suhaila Abd Muid<sup>1,2</sup>, Seok Mui Wang<sup>1,2</sup>

<sup>1</sup>Institute of Pathology, Laboratory, and Forensic Medicine, Universiti Teknologi MARA UiTM, Malaysia

<sup>2</sup>Faculty of Medicine, Universiti Teknologi MARA UiTM, Malaysia

<sup>3</sup>Faculty of Dentistry, Universiti Teknologi MARA UiTM, Malaysia

OP1-04 **Comparison of on-statin lipid & lipoprotein levels for residual cardiovascular risk prediction in type 2 diabetes**

Ji Yoon Kim<sup>1</sup>, Nam Hoon Kim<sup>1\*</sup>, Jimi Choi<sup>1</sup>, Sin Gon Kim<sup>1</sup>

<sup>1</sup>Endocrinology, Korea University College of Medicine, Korea

## Oral Presentation 2 (Korean)

Day 2 (Sep. 16\_Fri) 15:15-16:15, Room 1 (3F)

Chairperson Yoo-wook Kwon (Seoul National University, Korea)

Panels A-Hyun Cho (The Catholic University of Korea, Korea),  
Junhwa Hong (Eulji University, Korea)

OP2-01 **Prediction of future vascular events from thrombus analysis of Ischemic myopathy (TAOISM)**

Jeong-Min Kim<sup>1\*</sup>, Suh Min Kim<sup>2</sup>, Sun-Uk Hong<sup>3</sup>

<sup>1</sup>Neurology, Seoul National University Hospital, Korea

<sup>2</sup>Surgery, Chung-Ang University, Korea

<sup>3</sup>Pathology, Chung-Ang University, Korea

OP2-02 **Comparison of single-pill combination of moderate-intensity rosuvastatin & ezetimibe versus high-intensity rosuvastatin in atherosclerotic cardiovascular disease patients with type 2 diabetes**

Hyo-In Choi<sup>1</sup>, Byung Jin Kim<sup>1,2\*</sup>, Seung Jin Oh<sup>2</sup>, Yun Hyeong Cho<sup>3</sup>, Yong Hyun Park<sup>3</sup>, Tae Hyun Yang<sup>5</sup>, Joon Hyung Doh<sup>6</sup>, Young Joon Hong<sup>7</sup>, Kye Taek Ahn<sup>8</sup>, Jin Man Cho<sup>9</sup>

<sup>1</sup>Cardiology, Kangbuk Samsung Hospital, Korea

<sup>2</sup>Cardiology, National Health Insurance Service Ilsan Hospital, Korea

<sup>3</sup>Cardiology, Myongji Hospital Hanyang University College of Medicine, Korea

<sup>4</sup>Cardiology, Department of Internal Medicine Pusan National University Yangsan Hospital, Korea

<sup>5</sup>Department of Medicine, Inje University College of Medicine Busan Paik Hospital, Korea

<sup>6</sup>Department of Medicine, Inje University Ilsan Paik Hospital, Korea

<sup>7</sup>Internal Medicine, Chonnam National University Hospital, Korea

<sup>8</sup>Cardiology, Chungnam National University Hospital, Korea

<sup>9</sup>Department of Cardiovascular Medicine, Kyung Hee University, Korea

OP2-03 **Protocatechuic acid prevents heart failure in isoproterenol-infused mice by downregulating Kmo**

Hae Jin Kee<sup>1\*</sup>, Liyan Bai<sup>1</sup>, Xiongyi Han<sup>1</sup>, Myung Ho Jeong<sup>1</sup>

<sup>1</sup>Chonnam National University Hospital, Korea

OP2-04 **Rh1 ginsenoside suppressed lipopolysaccharide-induced endothelial cell inflammation & apoptosis by inhibiting endoplasmic reticulum stress & TLR4-mediated STAT3/NF- $\kappa$ B pathway**

Yujin Jin<sup>1</sup>, Kyung Sun Heo<sup>1\*</sup>, Thuy Le Lam Nguyen<sup>1</sup>, Chang Seon Myung<sup>1</sup>

<sup>1</sup>Pharmacy, Chungnam National University, Korea

## Oral Presentation 3

---

Day 2 (Sep. 16\_Fri) 15:15-16:15, Room 2 (3F)

Chairpersons Hyuk-Sang Kwon (The Catholic University of Korea, Korea),  
Sungha Park (Yonsei University, Korea)

Panels Hyun Min Kim (Chung-Ang University, Korea),  
Su Jin Jeong (Sejong General Hospital, Korea)

- OP3-01 **Cardiovascular risk factor profiles of familial hypercholesterolaemia patients with & without pathogenic FH candidate gene variants in the Malaysian community**  
Aimi Zafira Razman<sup>1,2</sup>, Hapizah Nawawi<sup>1,2\*</sup>, Noor Alicezah Mohd Kasim<sup>1,2</sup>, Alyaa AlKhateeb<sup>1,2</sup>, Siti Hamimah Sheikh Abdul Kadir<sup>1,2</sup>, Yung-An Chua<sup>1</sup>  
<sup>1</sup>*Institute of Pathology Laboratory and Forensic Medicine IPPerForM, Universiti Teknologi MARA, Malaysia*  
<sup>2</sup>*Faculty of Medicine, Universiti Teknologi MARA, Malaysia*
- OP3-02 **Impact of genetic testing on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia (GenTLe-FH): a randomized waiting list controlled open-label trial**  
Akihiro Nomura<sup>1</sup>, Hayato Tada<sup>1\*</sup>  
<sup>1</sup>*Cardiology, Kanazawa University Graduate School of Medical Sciences, Japan*
- OP3-03 **Dyslipidemia & type 2 diabetes among Filipino adults**  
Cherry Ann Durante<sup>1,2\*</sup>  
<sup>1</sup>*Nursing, Emilio Aguinaldo College Manila, the Philippines*  
<sup>2</sup>*Nursing, University of Perpetual Help Dr. Jose G Tamayo Medical Univ, the Philippines*
- OP3-04 **The relationship between total cholesterol level & oxidative stress in the liver tissue of the hyperlipidemic rat model after the intervention with synbiotic beverage**  
Rafik Prabowo<sup>1\*</sup>, Saosanti Mariana<sup>2</sup>  
<sup>1</sup>*Exercise Physiology, Universitas Islam Indonesia, Indonesia*  
<sup>2</sup>*Food & Nutrition, Universitas Islam Indonesia, Indonesia*
- OP3-05 **Determination of pathogenicity in ABCG5 & ABCG8 gene among Japanese dyslipidemic patients**  
Nobuko Kojima<sup>1\*</sup>, Hayato Tada<sup>1</sup>, Akihiro Nomura<sup>1</sup>, Hirofumi Okada<sup>1</sup>, Kenji Sakata<sup>1</sup>, Soichiro Usui<sup>1</sup>, Masaaki Kawashiri<sup>1</sup>, Masayuki Takamura<sup>1</sup>  
<sup>1</sup>*Cardiology, Kanazawa University, Japan*

## Oral Presentation 4 (Korean)

---

Day 3 (Sep. 17\_Sat) 13:35-14:35, Room 1 (3F)

Chairperson Kyung-Sun Heo (Chungnam National University, Korea)

Panels Se Eun Park (Sungkyunkwan University, Korea),  
Mi Hye Seo (Soonchunhyang University, Korea)

OP4-01 **Evaluation of the paradoxical association between lipid levels & incident atrial fibrillation according to statin usage: a nationwide cohort study**

Hyo-Jeong Ahn<sup>1</sup>, Eue-Keun Choi<sup>1,2\*</sup>, So-Ryoung Lee<sup>1</sup>, Seung-Woo Lee<sup>3</sup>, Kyung-Do Han<sup>4</sup>,  
Soonil Kwon<sup>1</sup>, Seil Oh<sup>1,2</sup>, Gregory Y H Lip<sup>2,5,6</sup>

<sup>1</sup>Internal Medicine, Seoul National University Hospital, Korea

<sup>2</sup>Internal Medicine, Seoul National University College of Medicine, Korea

<sup>3</sup>College of Medicine, The Catholic University of Korea, Korea

<sup>4</sup>Department of Statistics and Actuarial Science, Soongsil University, Korea

<sup>5</sup>University of Liverpool and Liverpool Chest Heart Hospital, United Kingdom

<sup>6</sup>Department of Clinical Medicine, Aalborg University, Denmark

OP4-02 **Comparison of cerebro-cardiovascular prognosis between cholesterol exposure estimate & cholesterol variability**

Hyung Joon Joo<sup>1\*</sup>, Sungmin Koh<sup>2</sup>, Yunjin Yum<sup>3</sup>, Yong Hyun Kim<sup>4</sup>, Eung Ju Kim<sup>5</sup>

<sup>1</sup>Cardiology, Korea University Anam Hospital, Korea

<sup>2</sup>Internal Medicine, Korea University Anam Hospital, Korea

<sup>3</sup>Biostatistics, Korea University College of Medicine, Korea

<sup>4</sup>Cardiology, Korea University Ansan Hospital, Korea

<sup>5</sup>Cardiology, Korea University Guro Hospital, Korea

OP4-03 **Early change in glucose level & risk of new-onset diabetes in patients initiating statin treatment**

Choongki Kim<sup>1\*</sup>

<sup>1</sup>Cardiology, Ewha Womans University College of Medicine Seoul Hospital, Korea

OP4-04 **Low-density lipoprotein cholesterol level, statin use & myocardial infarction risk in young adults**

Mee Kyung Kim<sup>1\*</sup>, Heekyoung Jeong<sup>1</sup>, Kyungdo Han<sup>2</sup>, Soon Jib Yoo<sup>1</sup>

<sup>1</sup>Endocrinology, The Catholic University of Korea, Korea

<sup>2</sup>Department of Statistics and Actuarial Science, Soongsil University, Korea

## Oral Presentation 5

---

Day 3 (Sep. 17\_Sat) 13:35-14:35, Room 2 (3F)

Chairperson Eun Seok Kang (Yonsei University, Korea)

Panels Yong-ho Lee (Yonsei University, Korea),  
Ji-won Hwang (Inje University, Korea)

OP5-01 **Ginsenoside Rh1 abolishes ROS-dependent KLF4 signaling pathway to inhibit proliferation & migration of vascular smooth muscle cells**

Diem Thi Ngoc Huynh<sup>1</sup>, Kyung-Sun Heo<sup>1\*</sup>, Thuy Le Lam Nguyen<sup>1</sup>

<sup>1</sup>Pharmacology, College of Pharmacy, Chungnam National University, Korea

OP5-02 **PCSK9 inhibitors inhibit monocyte adherence to stimulated human coronary artery endothelial cells**

Rahayu Zulkapli<sup>1,2,3</sup>, Hapizah Nawawi<sup>1,2\*</sup>, Suhaila Abd Muid<sup>1,2</sup>, Seok Mui Wang<sup>1,2</sup>

<sup>1</sup>Institute of Pathology, Laboratory, and Forensic Medicine, Universiti Teknologi MARA UiTM, Malaysia

<sup>2</sup>Faculty of Medicine, Universiti Teknologi MARA UiTM, Malaysia

<sup>3</sup>Faculty of Dentistry, Universiti Teknologi MARA UiTM, Malaysia

OP5-03 **Lipoprotein(a) & cardiovascular & all-cause mortality in Korean adults**

Byung Jin Kim<sup>1\*</sup>, Mi Yeon Lee<sup>2</sup>, Min Jung Kwon<sup>3</sup>

<sup>1</sup>Cardiology, Kangbuk Samsung Hospital Sungkyunkwan University School of Medicine, Korea

<sup>2</sup>Division of Biostatistics Department of RD Management, Kangbuk Samsung Hospital Sungkyunkwan University School of Medicine, Korea

<sup>3</sup>Department of Laboratory Medicine, Kangbuk Samsung Hospital Sungkyunkwan University School of Medicine, Korea

OP5-04 **Saffron: a potential natural alternative remedy for statin intolerance**

Iman Nabilah Abd Rahim<sup>1,2</sup>, Noor Alicezah Mohd Kasim<sup>1,2\*</sup>, Effat Omar<sup>1,2</sup>, Suhaila Abd Muid<sup>1,2</sup>, Hapizah Md Nawawi<sup>1,2</sup>

<sup>1</sup>Institute of Pathology, Universiti Teknologi MARA, Malaysia

<sup>2</sup>Faculty of Medicine, Universiti Teknologi MARA, Malaysia



## **Moderated Poster Presentation**

The 11<sup>th</sup> International Congress on Lipid & Atherosclerosis  
with Asian-Pacific Society of Atherosclerosis and Vascular Disease

## Moderated Poster Presentation

### Moderated Poster Presentation 1 (Korean)

---

• Date & Time: Sep 16 (Fri) 15:15-15:55 • Place: Studio 8,9,10 Poster Hall (6F)

Chairperson So Hun Kim (Inha University, Korea)

Panels Sung Ai Kim (Hallym University, Korea), Jae Hyuk Lee (Myongji Hospital, Korea)

**MP1-01 Oasl1 deficiency promotes eNOS mRNA degradation, accelerating endothelial dysfunction & atherogenesis**

Tae Kyeong Kim<sup>1</sup>, Goo Taeg Oh<sup>\*</sup>

<sup>1</sup>Basic Science, Ewha Womans University, Korea

**MP1-02 Loss of myeloid-PCSK9 improves cardio-protection against acute myocardial infarction**

Shin Hye Moon<sup>1</sup>, Goo Taeg Oh<sup>1\*</sup>, Na Hyeon Yoon<sup>1</sup>

<sup>1</sup>Life Science, Heart Immune Brain Network Research Center, Ewha Womans University, Korea

**MP1-03 Peroxiredoxin 3 preserves cardiac function by regulating mitochondrial quality control**

Seong Keun Sonn<sup>1</sup>, Goo Taeg Oh<sup>\*</sup>

<sup>1</sup>Basic Science, Ewha Womans University, Basic Science, Korea

**MP1-04 HMGB1 mediates MCP-1 expression in mechanically stressed vascular smooth muscle cells**

Ji Won Kim<sup>1,2</sup>, Chi Dae Kim<sup>1,2,3\*</sup>, Jong Min Choi<sup>1</sup>, Ju Yeon Kim<sup>1,2</sup>, Eun Yeong Jeon<sup>1</sup>

<sup>1</sup>Pharmacology, School of Medicine Pusan National University, Korea

<sup>2</sup>Pharmacology, Gene Cell Therapy Research Center for Vessel-associated Diseases Pusan National University, Korea

<sup>3</sup>Pharmacology, Research Institute for Convergence of Biomedical Science and Technology Pusan National University, Korea

## Moderated Poster Presentation 2

---

• Date & Time: Sep 16 (Fri) 15:15-15:55 • Place: Studio 7 Poster Hall (6F)

Chairperson Ung Kim (Yeungnam University, Korea)

Panels Yong Sook Kim (Chonnam National University, Korea),  
Heung Yong Jin (Jeonbuk National University, Korea)

**MP2-01 Cr6 interacting factor 1 deficiency increases homocysteine production in vascular endothelial cells**

Cuk Seong Kim<sup>1\*</sup>

<sup>1</sup>Physiology, Chungnam National University, Korea

**MP2-02 17  $\beta$ -estradiol increases APE1/Ref-1 secretion in vascular endothelial cells : involvement of calcium-dependent exosome pathway**

Yu Ran Lee<sup>1,2</sup>, Byeong Hwa Jeon<sup>1,2\*</sup>, Hee Kyoung Joo<sup>1,2</sup>, Eun Ok Lee<sup>1,2</sup>, Sungmin Kim<sup>1,2</sup>, Hao Jin<sup>1,2</sup>, Yeon Hee Choi<sup>1,2</sup>

<sup>1</sup>Physiology, School of Medicine, Chungnam National University, Korea

<sup>2</sup>Basic Science, Research Institute of Medical Sciences Chungnam National University, Korea

**MP2-03 PFKFB3 & its role on ECM dependent vascular inflammation**

Jenita Immanuel<sup>1</sup>, Sanguk Yun<sup>1\*</sup>

<sup>1</sup>Biotechnology, Inje University, Korea

**MP2-04 PCSK9 deficient heart-derived ANP promotes cardiac survival after myocardial infarction.**

Na Hyeon Yoon<sup>1</sup>, Goo Taeg Oh<sup>1\*</sup>, Shin Hye Moon<sup>1</sup>

<sup>1</sup>Heart Immune Brain Network Research Center, Korea



### Moderated Poster Presentation 3 (Korean)

---

• Date & Time: Sep 17 (Sat) 13:35-14:15 • Place: Studio 8,9,10 Poster Hall (6F)

Chairperson Sung-Wan Chun (Soonchunhyang University, Korea)

Panels Kyung-Soo Kim (CHA University, Korea),  
Han Seok Choi (Dongguk University, Korea)

**MP3-01 Autocrine regulation of cellular migration by secreted molecules from mechanically stressed vascular smooth muscle cells**

Ju Yeon Kim<sup>1,2</sup>, Chi Dae Kim<sup>1,2,3\*</sup>, Ji Won Kim<sup>1,2</sup>, Eun Yeoung Jeon<sup>1</sup>

<sup>1</sup>Pharmacology, School of Medicine Pusan National University

<sup>2</sup>Pharmacology, Gene Cell Therapy Research Center for Vessel-associated Diseases Pusan National University, Korea

<sup>3</sup>Pharmacology, Research Institute for Convergence of Biomedical Science and Technology Pusan National University, Korea

**MP3-02 Depression & subclinical coronary atherosclerosis in adults without clinical coronary artery disease**

Gyung-Min Park<sup>1\*</sup>, Yong-Giun Kim<sup>1</sup>, Jangho Park<sup>2</sup>

<sup>1</sup>Cardiology, Ulsan University Hospital, Korea

<sup>2</sup>Psychiatry, Ulsan University Hospital, Korea

**MP3-03 Effect of lifestyle modification on the improvement of obesity, metabolic parameters & adipo-myokine related risk in overweight/obese adults**

Mi Ri Ha<sup>1</sup>, Oh Yoen Kim<sup>1,2\*</sup>, Jihyun Park<sup>1</sup>, Ye Jin Kim<sup>1</sup>, Chae Rin Kim<sup>1</sup>, Su Min Hwang<sup>1</sup>, Hjo Jin Kim<sup>1</sup>

<sup>1</sup>Health Science, Dong-A University, Korea

<sup>2</sup>Food & Nutrition, Dong-A University, Korea

## Moderated Poster Presentation 4

• Date & Time: Sep 17 (Sat) 13:35-14:15 • Place: Studio 7 Poster Hall (6F)

Chairperson Su Yeon Choi (Seoul National University, Korea)

Panels Hoyoun Won (Chung-Ang University, Korea),  
Kae Won Cho (Soonchunhyang University, Korea)

**MP4-01 Mutation in CytB gene associated with macrophage intracellular lipid metabolism**

Vasily Sukhorukov<sup>1\*</sup>, Victoria Khotina<sup>2</sup>, Igor Sobenin<sup>2</sup>

<sup>1</sup>Basic Science, Institute for Atherosclerosis Research, Russia

<sup>2</sup>Basic Science, Institute of General Pathology and Pathophysiology, Russia

**MP4-02 Human milk oligosaccharides attenuate lipopolysaccharide-induced endothelial hyper-permeability & migration**

Dung Van Nguyen<sup>1</sup>, Kyung-Sun Heo<sup>1\*</sup>, Yujin Jin<sup>1</sup>, Thuy Le Lam Nguyen<sup>1</sup>, Lila Kim<sup>2</sup>

<sup>1</sup>Pharmacology, College of Pharmacy, Chungnam National University, Korea

<sup>2</sup>Food & Nutrition, GeneChem Inc., Korea

**MP4-03 Modeling of low-density lipoprotein desialylation processes in mice**

Dmitry Kashirskikh<sup>1,2,3\*</sup>, Evgeny Bezsonov<sup>1,3</sup>, Nelya Yakhina<sup>2</sup>, Igor Sobenin<sup>3,4</sup>, Alexander Orekhov<sup>1,2</sup>

<sup>1</sup>Basic Science, Petrovsky National Research Centre of Surgery, Russia

<sup>2</sup>Basic Science, Institute for Atherosclerosis Research, Russia

<sup>3</sup>Basic Science, Institute of General Pathology and Pathophysiology, Russia

<sup>4</sup>Basic Science, Institute of Experimental Cardiology, Russia

**MP4-04 Tyrosine residues of mitochondrial creatine kinase mitigate hypoxia/reoxygenation injury in the heart through phosphorylation**

Maria Victoria Faith Garcia<sup>1,2,4</sup>, Jin Han<sup>1,2,5\*</sup>, Nammi Park<sup>1</sup>, Jubert Marquez<sup>1,2,4</sup>, Chang Shin Yoon<sup>1</sup>, Ipppei Shimizu<sup>3</sup>, Sung Ryul Lee<sup>1</sup>, Hyoung Kyu Kim<sup>1,2,5</sup>

<sup>1</sup>Cardiology, Cardiovascular and Metabolic Disease Center, Smart Marine Therapeutics Center, Inje University, Korea

<sup>2</sup>Health Sciences and Technology, Graduate School of Inje University, Korea

<sup>3</sup>Cardiology, Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Japan

<sup>4</sup>Biology Department, De La Salle University Manila, the Philippines

<sup>5</sup>Physiology, College of Medicine, Inje University, the Philippines

## Moderated Poster Presentation 5 (APSAVD Young Investigator)

• Date & Time: Sep 16 (Fri) 15:05-15:55 • Place: Studio 8,9,10 Poster Hall (6F)

**MP5-01 Fenofibrate lowers cardiac lipid accumulation & attenuates diabetic cardiomyopathy in db/db mice**

Jiwon Park<sup>1\*</sup>, Changmyung Oh<sup>1</sup>

<sup>1</sup>*Biomedical Science and Engineering, Gwangju Institute of Science and Technology (GIST), Korea*

**MP5-02 In vitro & in silico inhibition of IL-6 & NF-κB by Nigella sativa oil & thymoquinone as potential anti atherogenic agent**

Al aina Yuhainis Firus Khan<sup>1</sup>, Hapizah Nawawi<sup>1,2\*</sup>, Suhaila Abd Muid<sup>1,2</sup>, Thuhairah Abdul Rahman<sup>1,2</sup>

<sup>1</sup>*IPPerForM, Institute of Pathology Laboratory and Forensic Medicine, Universiti Teknologi MARA, Malaysia*

<sup>2</sup>*Biochemistry and Molecular Medicine, Faculty of Medicine, Universiti Teknologi MARA, Malaysia*

**MP5-03 Coronary risk factor profile amongst premature coronary artery disease patients according to different age categories**

Sukma Azureen Nazli<sup>1,2</sup>, Hapizah Nawawi<sup>1,2\*</sup>, Noor Alicezah Mohd Kasim<sup>2</sup>, Ahmad Zia Ul-Saufie Mohamad Japeri<sup>3</sup>, Azhari Rosman<sup>4</sup>, Sazzli Kasim<sup>2</sup>, Khairul Shafiq Ibrahim<sup>2</sup>

<sup>1</sup>*Universiti Teknologi MARA, Institute for Pathology Laboratory and Forensic Medicine IPPerForM, Malaysia*

<sup>2</sup>*Faculty of Medicine, Universiti Teknologi MARA, Malaysia*

<sup>3</sup>*Faculty of Computer and Mathematical Sciences, Universiti Teknologi MARA, Malaysia*

<sup>4</sup>*Cardiology, National Heart Institute, Malaysia*

**MP5-04 Genetic variations of ABCG5 & ABCG8 genes among clinically diagnosed fh patients attending primary care clinics in Malaysia**

Yung An Chua<sup>1</sup>, Hapizah Nawawi<sup>1,2\*</sup>, Nur Syahirah Shahuri<sup>1,2</sup>, Alyaa al-Khateeb<sup>1,2</sup>, Noor Alicezah Mohd Kasim<sup>1,2</sup>, Siti Hamimah Sheikh Abdul Kadir<sup>1,2</sup>, Anis Safura Ramli<sup>1,2</sup>

<sup>1</sup>*Institute of Pathology Laboratory and Forensic Medicine IPPerForM, Other Professional, Malaysia*

<sup>2</sup>*Universiti Teknologi MARA, Other Professional, Malaysia*

**MP5-05 Genetic landscape of pathogenic variants in familial hypercholesterolaemia candidate genes among patients attending primary care clinics in Malaysia**

Nur Syahirah Shahuri<sup>1,2</sup>, Hapizah Nawawi<sup>1,2\*</sup>, Alyaa R Al-Khateeb<sup>1,2</sup>, Yung-An Chua<sup>1</sup>, Siti Hamimah Sheikh Abdul Kadir<sup>1,2</sup>, Noor Alicezah Mohd Kasim<sup>1,2</sup>, Anis Safura Ramli<sup>1,2</sup>

<sup>1</sup>*Institute of Pathology Laboratory and Forensic Medicine IPPerForM, Universiti Teknologi MARA, Malaysia*

<sup>2</sup>*Faculty of Medicine, Universiti Teknologi MARA, Malaysia*

**MP5-06 Prediction rate of pathogenic variants diagnosed by various diagnostic criteria among familial hypercholesterolaemic patients attending primary care clinics**

Sukma Azureen Nazi<sup>1,2</sup>, Hapizah Nawawi<sup>1,2\*</sup>, Nur Syahirah Shahuri<sup>1,2</sup>, Alyaa al-Khateeb<sup>2</sup>, Noor Alicezah Mohd Kasim<sup>2</sup>, Siti Hamimah Sheikh Abdul Kadir<sup>2</sup>, Yung-An Chua<sup>1,2</sup>, Anis Safura Ramli<sup>1,2</sup>

<sup>1</sup>*Institute for Pathology Laboratory and Forensic Medicine IPPerForM, Universiti Teknologi MARA, Malaysia*

<sup>2</sup>*Faculty of Medicine, Universiti Teknologi MARA, Malaysia*

**MP5-07 Pharmacologic activation of angiotensin-converting enzyme II alleviates diabetic cardiomyopathy in db/db mice by reducing reactive oxidative stress**

Woo ju Jeong<sup>1</sup>, Chang Myung Oh<sup>1\*</sup>, Dong Hyun Kim<sup>1</sup>, Yumin Kim<sup>1</sup>, Jibeom Lee<sup>1</sup>, Sung Woo Cho<sup>2,3</sup>, Raekil Park<sup>1</sup>

<sup>1</sup>*Basic Science, GIST, Korea*

<sup>2</sup>*Cardiology, Ilsan Paik Hospital, Cardiology, Korea*

<sup>3</sup>*Cardiology, Inje University College of Medicine, Korea*

**MP5-08 Body type parameters predict cerebral small vessel disease**

Ki-Woong Nam<sup>1\*</sup>, Hyung Min Kwon<sup>1</sup>

<sup>1</sup>*Neurology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Korea*

**MP5-09 A comparison of statin treatment algorithms for primary prevention in statin-naive Filipino patients**

Bayani Pocholo Maglinte<sup>1\*</sup>, Alex Junia<sup>1,2</sup>, Jeremyjones Robles<sup>1,3</sup>

<sup>1</sup>*Internal Medicine, Cebu Velez General Hospital, the Philippines*

<sup>2</sup>*Cardiology, Cebu Velez General Hospital, the Philippines*

<sup>3</sup>*Endocrinology, Cebu Velez General Hospital, the Philippines*





# Poster Exhibition

The 11<sup>th</sup> International Congress on Lipid & Atherosclerosis  
with Asian-Pacific Society of Atherosclerosis and Vascular Disease

## Poster Exhibition

### Basic science of lipids & lipoproteins / Basic science of atherosclerosis

- P1-02 Proteomic characterization of peripheral leukocytes in variant carriers of CDKAL1 associated with cholesterol efflux capacity**  
Soo jin Ann<sup>1</sup>, Sang-Hak Lee<sup>1\*</sup>  
<sup>1</sup>Cardiology, Yonsei University College of Medicine, Korea
- P1-03 Anti-hyperlipidaemic effects of carboxymethyl chitosan loaded - Ficus deltoidea var. Kunstleri standardised acid ethanolic extract in diet-induced hypercholesterolaemic rabbits**  
Faiqah Ramli<sup>1</sup>, Suhaila Abd Muid<sup>1,2\*</sup>, Amirah Mohd Ariff<sup>1</sup>, Effat Omar<sup>1,2</sup>, Noor Alicezah Mohd Kasim<sup>1,2</sup>, Teh Lay Kek<sup>3,4</sup>, Hapizah Nawawi<sup>1,2</sup>  
<sup>1</sup>Institute of Pathology Laboratory and Forensic Medicine IPPerForM, Universiti Teknologi MARA, Malaysia  
<sup>2</sup>Preventive Medicine, Faculty of Medicine, Universiti Teknologi MARA, Malaysia  
<sup>3</sup>Pharmacy, Faculty of Pharmacy, Universiti Teknologi MARA, Malaysia  
<sup>4</sup>Pharmacy, Integrative Pharmacogenomics Institute iPROMISE, Universiti Teknologi MARA, Malaysia
- P1-06 Analysis of the effect of variations in nicotine concentration on vape use on plasma malondialdehyde (MDA): in vivo study**  
Putri Ranasyafa Aura Hidayat<sup>1</sup>, Rizki Fajar Utami<sup>2\*</sup>, Dwi Nur Ahsani<sup>3</sup>  
<sup>1</sup>Undergraduate Medical Student, Islamic University of Indonesia, Indonesia  
<sup>2</sup>Biochemistry, Islamic University of Indonesia, Indonesia  
<sup>3</sup>Histology, Islamic University of Indonesia, Indonesia
- P1-07 Effect of ferroptosis by iron overload on non-alcoholic steatohepatitis and atherosclerosis**  
E-Poster Koki Honma<sup>1</sup>, Shogo Watanabe<sup>3\*</sup>, Hinako Nakayama<sup>1</sup>, Sora Kirihara<sup>1</sup>, Ikumi Sato<sup>1</sup>, Eito Matsumoto<sup>2</sup>, Sana Matsusita<sup>2</sup>, Tomona Kaihara<sup>2</sup>, Taketo Fukuoka<sup>2</sup>, Shusei Yamamoto<sup>3</sup>, Satoshi Hirohata<sup>3</sup>  
<sup>1</sup>Medical Technology, Graduate School of Health Science Okayama University, Japan  
<sup>2</sup>Medical Technology, Faculty of Health Science Okayama University, Japan  
<sup>3</sup>Faculty of Health Science, Okayama University, Japan
- P1-08 Antihepatotoxicity potential of  $\alpha$ -Linolenic acid in high fat-diet/alloxaninduced diabetes in female rats**  
E-Poster Sumit Rajput<sup>1\*</sup>, Priya Tiwari<sup>1</sup>  
<sup>1</sup>Physiology, B V Deemed University, India
- P1-09 PRDX5 exacerbates atherosclerosis through TLR4 activation in endothelial cell**  
Hyae Yon Kweon<sup>1</sup>, Goo Taeg Oh<sup>1\*</sup>, Eun Ju Song<sup>1</sup>, Soon Ho Lee<sup>1</sup>, Doyeon Kim<sup>1</sup>  
<sup>1</sup>Basic Science, Ewha Womans University, Korea

**P1-10 Endothelial PTP mitigates vascular inflammation via USF1/A20 axis-mediated NF- $\kappa$ B inactivation**

Min Ji Cho<sup>1</sup>, Jong-Gil Park<sup>1\*</sup>

<sup>1</sup>Basic Science, Biotherapeutics Translational Research Center, Korea

**P1-11 Flow and ECM-dependent endothelial SGK-1 regulation**

Yeeun Jang<sup>1\*</sup>

<sup>1</sup>Basic Science, Inje University, Korea

**P1-12 Novel function of SHANK3 on vascular inflammation**

Jinri Lee<sup>1</sup>, Sanguk Yun<sup>1\*</sup>

<sup>1</sup>Basic Science, Inje University, Korea

**P1-13 GLP-1RAs inhibit high phosphate-induced vascular calcification and angiotensin II-induced proliferation and migration in rat vascular smooth muscle cells**

Jinmi Lee<sup>1</sup>, Won Young Lee<sup>2\*</sup>, Seok Woo Hong<sup>1</sup>, Min Jeong Kim<sup>1</sup>, Sun Joon Moon<sup>2</sup>, Hyemi Kwon<sup>2</sup>, Se Eun Park<sup>2</sup>, Eun-Jung Rhee<sup>2</sup>

<sup>1</sup>Endocrinology, Institute of Medical Research Kangbuk Samsung Hospital Sungkyunkwan University School of Medicine, Korea

<sup>2</sup>Endocrinology, Department of Endocrinology and Metabolism Kangbuk Samsung Hospital Sungkyunkwan University School of Medicine, Korea

**P1-15 The role of secretory APE1/Ref-1 in atherosclerotic inflammation**

Hee Kyoung Joo<sup>1,2</sup>, Byeong Hwa Jeon<sup>1,2\*</sup>, Yu Ran Lee<sup>1,2</sup>, Eun-ok Lee<sup>1,2</sup>, Sungmin Kim<sup>1,2</sup>, Hao Jin<sup>1,2</sup>, Yeon-hee Choi<sup>1,2</sup>, Eun Ju Choi<sup>2</sup>, Jee Su Kim<sup>2</sup>

<sup>1</sup>Basic Science, Department of Physiology, College of Medicine, Chungnam National University, Korea

<sup>2</sup>Basic Science, Research Institute for Medical Sciences, College of Medicine, Chungnam National University, Korea

**P1-16 Transcriptome profile between brain of ischemic stroke model and Alzheimer's disease model**

Juhyun Song<sup>1\*</sup>

<sup>1</sup>Department of anatomy, Chonnam National University Medical School, Korea

**P1-17 Comparing the long non-coding RNA expression profiles of skeletal muscle and kidney tissues from patients with diabetes**

Young-Kook Kim<sup>1\*</sup>

<sup>1</sup>Basic Science, Chonnam National University Medical School, Korea



**P1-20 SGLT2 inhibitor would attenuate myeloperoxidase induced vascular inflammation in hyperglycemic mice**

Dae-Yeon Kim<sup>1</sup>, Sung Wan Chun<sup>1\*</sup>, Jong-Seok Moon<sup>2</sup>, Hyeon-Seok Cheon<sup>3</sup>

<sup>1</sup>Endocrinology, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Korea

<sup>2</sup>Basic Science, Department of Integrated Biomedical Science, Soonchunhyang Institute of Medibio Science SIMS, Soonchunhyang University, Korea

<sup>3</sup>Basic Science, Department of Biology, College of Natural Sciences, Soonchunhyang University, Korea

**P1-21 Single cell RNA sequencing reveals the functional heterogeneity of Peroxiredoxin1 positive microglia regulates cell death and inflammation against stroke brain damage**

Sinai Kim<sup>1</sup>, Goo Taeg Oh<sup>1\*</sup>

<sup>1</sup>Basic Science, HeartImmuneBrain Network Research Center, Department of Life Science, Ewha Womans University, Korea

**P1-22 Rottlerin induces de novo adipogenesis and inhibition of adipogenesis via the LRP/mTOR/SREBP1C pathway**

Ye Jin Kim<sup>1</sup>, Gwang-woong Go<sup>1\*</sup>

<sup>1</sup>Food & Nutrition, Hanyang University, Korea

**P1-23 Pharmacokinetic profiles of vitexin and isovitexin in carboxymethyl chitosan loaded-Ficus deltoidea extract for treatment of atherosclerosis**

Faiqah Ramli<sup>1</sup>, Suhaila Abd Muid<sup>1,2\*</sup>, Wong Tin Wui<sup>3,4</sup>, Teh Lay Kek<sup>3,5</sup>, Mohd Zaki Salleh<sup>3,5</sup>, Hapizah Nawawi<sup>1,2</sup>

<sup>1</sup>Institute of Pathology Laboratory and Forensic Medicine IPPerForM, Universiti Teknologi MARA UiTM, Malaysia

<sup>2</sup>Preventive Medicine, Faculty of Medicine, Universiti Teknologi MARA UiTM, Malaysia

<sup>3</sup>Faculty of Pharmacy, Universiti Teknologi MARA UiTM, Malaysia

<sup>4</sup>Integrative Pharmacogenomics Institute iPROMISE, Universiti Teknologi MARA UiTM, Malaysia

<sup>5</sup>Non Destructive Biomedical and Pharmaceutical Research Centre, Smart Manufacturing Research Institute, Universiti Teknologi MARA UiTM, Malaysia

## Clinical lipidology & genetics / Clinical vascular disease & nutrition

### P2-01 Acute coronary syndrome in young Indonesian

Mega Febrionora<sup>1\*</sup>, Chaerul Achmad<sup>1</sup>

<sup>1</sup>Cardiology, Hasan Sadikin General Hospital, Indonesia

### P2-02 Association between lipid profiles and the risk of incident early-onset vasomotor symptoms

Hye Rin Choi<sup>1,2</sup>, Seungho Ryu<sup>1,3,4\*</sup>, Yoosoo Chang<sup>1,3,4</sup>, Yejin Kim<sup>1</sup>, Jeonggyu Kang<sup>1</sup>, Min Jung Kwon<sup>1,6</sup>, Ria Kwon<sup>1,2</sup>, Ga young Lim<sup>1,2</sup>, Kye Hyun Kim<sup>7</sup>, Hoon Kim<sup>8</sup>, Yun Soo Hong<sup>9</sup>, Di Zhao<sup>9</sup>, Juhee Cho<sup>1,4,9</sup>, Eliseo Guallar<sup>9</sup>, Hyun Young Park<sup>10</sup>

<sup>1</sup>Center for cohort studies, Kangbuk Samsung Hospital, Korea

<sup>2</sup>Institute of medical research, Sungkyunkwan University School of Medicine, Korea

<sup>3</sup>Occupational and Environmental medicine, Kangbuk Samsung Hospital, Korea

<sup>4</sup>Clinical Research Design Evaluation, Sungkyunkwan University, Korea

<sup>5</sup>Total Healthcare Center, Kangbuk Samsung Hospital, Korea

<sup>6</sup>Laboratory Medicine, Kangbuk Samsung Hospital, Korea

<sup>7</sup>Obstetrics and Gynecology, Kangbuk Samsung Hospital, Korea

<sup>8</sup>Obstetrics and Gynecology, Seoul National University College of Medicine, Korea

<sup>9</sup>Epidemiology and Medicine, Johns Hopkins University Bloomberg School of Public Health, United States of America

<sup>10</sup>Precision Medicine, National Institute of Health Korea Disease Control and Prev, Korea

### P2-03 Age at first childbirth and hypertriglyceridemia among Korean women

Hye Rin Choi<sup>1,2</sup>, Hyeon Chang Kim<sup>3\*</sup>

<sup>1</sup>Center for Cohort studies, Kangbuk Samsung Hospital, Korea

<sup>2</sup>Medical Research, Sungkyunkwan University School of Medicine, Korea

<sup>3</sup>Preventive Medicine, Yonsei University College of Medicine, Korea

### P2-08 Shockwaves-treatment induces healthy hypertrophic adipocytes to high-fat diet in mice

Wonkyoung Cho<sup>1</sup>, Young Mi Park<sup>1\*</sup>

<sup>1</sup>Basic Science, Ewha Womans University, Korea

### P2-09 Overexpression & inhibition of DNAJC6, RMR-related gene, modulate adipogenetic physiology from 3T3-L1 preadipocytes

Dajeong Son<sup>1</sup>, Myoungsook Lee<sup>1,2\*</sup>

<sup>1</sup>Food & Nutrition, Sungshin Womens University, Korea

<sup>2</sup>Food & Nutrition, Research Institute of Obesity Science, Korea

**P2-11 The association between diet quality and dyslipidemia in Korean adults: results from Korea National Health and Nutrition Examination Survey 2007-2020**

Suyeon Lee<sup>1</sup>, Dahyun Park<sup>1\*</sup>, Juhee Lee<sup>1</sup>

<sup>1</sup>*Basic Science, Interdisciplinary Program in Precision Public Health Graduate School, Korea University, Korea*

**P2-13 The associations between ANRIL rs1333049 polymorphism and myocardial infarction susceptibility: a systematic review and meta-analysis**

Agil Noviar Alvirosa<sup>1\*</sup>, Hari Yudha Afrianto<sup>2</sup>, Rizki Febriawan<sup>3</sup>, Dahniar Rizki Fahriani<sup>4</sup>

<sup>1</sup>*Family Medicin, Muhammadiyah Lamongan Hospital, Indonesia*

<sup>2</sup>*Cardiology, Muhammadiyah Lamongan Hospital, Indonesia*

<sup>3</sup>*Family Medicine, Belitung Utama Hospital, Indonesia*

<sup>4</sup>*Family Medicine, Ibnu Sina Regional Hospital, Indonesia*

**P2-15 Inflammation, mitophagy, and apoptosis in human thoracic aorta aneurysm**

Vasily Sukhorukov<sup>1,2\*</sup>, Petr Chumachenko<sup>2</sup>, Zuhra Khasanova<sup>2</sup>, Anton Postnov<sup>2</sup>, Igor Sobenin<sup>1,2</sup>

<sup>1</sup>*Basic Science, FSBI Petrovsky National Research Centre of Surgery, Russia*

<sup>2</sup>*Basic Science, National Medical Research Center of Cardiology, Institute of Experimental Cardiology, Russia*

**P2-16 Association between early lipid lowering and myocardial contractility in patients with ST-segment elevation myocardial infarction**

Surenjav Chimed<sup>1\*</sup>

<sup>1</sup>*Heart and Lung Center, Leiden University Medical Center, Netherlands*

**P2-18 Efficacy and tolerability of rosuvastatin 5mg/ezetimibe 10mg versus rosuvastatin 20mg monotherapy meta-analysis of RCTs**

Sang-Hak Lee<sup>1\*</sup>, Yura Kang<sup>2</sup>, Jung Mi Park<sup>2</sup>

<sup>1</sup>*Cardiology, Yonsei University College of Medicine, Korea*

<sup>2</sup>*Biostatistics and Computing, Yonsei University, Korea*

**P2-19 Investigate the association between Vitamin D levels, vascular risk factors and inflammation in type 2 diabetic patients**

E-Poster

Vikas Sharma<sup>1\*</sup>, Madhu Gautam<sup>1</sup>

<sup>1</sup>*Neurology, S N Medical College and hospital, India*

**P2-21 Statin therapy decreases the risk for gastrointestinal bleeding and improves clinical outcome in atherosclerotic cardiovascular disease patients**

Niyata Hananta Karunawan<sup>1,2\*</sup>, Rizaldy Taslim Pinzon<sup>2</sup>

<sup>1</sup>*Preventive Medicine, Dr. Adhyatma MPH Tugurejo General Hospital, Indonesia*

<sup>2</sup>*Preventive Medicine, Duta Wacana Christian University, Indonesia*

- P2-23 Obesity/Metabolic Improvement in association with -3826A>G in the Uncoupling protein-1 and nutrition quotient after the Lifestyle Modification**  
Ji Hyun Park<sup>1</sup>, Oh Yoen Kim<sup>1,2\*</sup>, Mi Ri Ha<sup>1</sup>, Chae Rin Kim<sup>1</sup>, Ye Jin Kim<sup>1</sup>, Won Suk Ahn<sup>3</sup>  
<sup>1</sup>Health Science, Dong-A University, Korea  
<sup>2</sup>Food & Nutrition, Dong-A University, Korea  
<sup>3</sup>Nephrology, Dong-A University, Korea
- P2-24 Exercise-induced circulating irisin level is correlated with improved cardiac function in rats**  
Amy Kim<sup>1</sup>, Jin Han<sup>1,2\*</sup>, Dae Yun Seo<sup>1,2</sup>, Tae Nyun Kim<sup>1,2</sup>, Hyoung Kyu Kim<sup>1,2</sup>  
<sup>1</sup>Department of Physiology, Inje University College of Medicine, Cardiovascular and Metabolic Disease Center, National Research Laboratory for Mitochondrial Signaling, Korea  
<sup>2</sup>Basic Science, Inje University, Smart Marine Therapeutics Center, Korea
- P2-25 Corticosterone expression changes after ischemic brain damage**  
Huiju Jo<sup>1</sup>, Goo Taeg Oh<sup>1\*</sup>  
<sup>1</sup>Basic Science, Ewha Womans University, Korea
- P2-26 Novel marine compound Neopetroside A confers cardioprotection against ischemia/reperfusion injury**  
Jubert Marquez<sup>1,2,3</sup>, Jin Han<sup>1,2\*</sup>, Hyoung Kyu Kim<sup>1,2</sup>, Min Kim<sup>1,2</sup>, Nikolay Nifantiev<sup>4</sup>  
<sup>1</sup>Cardiovascular and Metabolic Disease Center, Inje University, Korea  
<sup>2</sup>Department of Health Sciences and Technology, Graduate School, Inje University, Korea  
<sup>3</sup>Department of Biology, De La Salle University, the Philippines  
<sup>4</sup>GB Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch of the Russian Academy of Science, Vladivostok, Russia
- P2-27 Socioeconomic status of people with hypertension in Indonesia: mitigation of risks for the impact of the COVID-19 pandemic**  
Rosinta Hotmaida Pebrianti Purba<sup>1\*</sup>, Asriati Asriati<sup>2</sup>  
<sup>1</sup>Basic Science, The Ministry of National Development Planning, Indonesia  
<sup>2</sup>Republic of Indonesia, Other Professional, Indonesia
- P2-28 The correlation between stress and fatigue in patients with systemic lupus erythematosus (SLE) in Indonesia during pandemic: cross-sectional study**  
Syafira Laila Nurulita<sup>1\*</sup>  
<sup>1</sup>Basic Science, Universitas Islam Indonesia, Indonesia
- P2-29 Prevalence of prehypertension among medical student during pandemic COVID-19 in Yogyakarta, Indonesia**  
Aviatna Kharima Sadida<sup>1\*</sup>, Fajar Alfa Saputra<sup>1</sup>, Muhammad Bherbudi Wicaksono<sup>1</sup>  
<sup>1</sup>Basic Science, Islamic University of Indonesia, Indonesia





## **Other Information**

The 11<sup>th</sup> International Congress on Lipid & Atherosclerosis  
with Asian-Pacific Society of Atherosclerosis and Vascular Disease

## Official & Social Program

### Welcome Reception

---

Location Room 3 (3F)  
Date & Time September 15 (Thu) 17:10

The organizing committee of ICoLA 2022 with APSAVD is pleased to invite all of participants and invited faculties to the welcome reception to celebrate the first day of ICoLA 2022 with APSAVD

### Opening Address

---

Location Room 1,2,3 (3F)  
Date & Time September 16 (Fri) 11:25-11:30

### 2022 KSoLA Award Ceremony for Scientific Excellence and Young Investigator

---

Location Room 3 (3F)  
Date & Time September 16 (Fri) 15:15-16:15

### Dinner

---

Location Studio 1,2,3 (6F)  
Date & Time September 16 (Fri) 17:55

### Closing Ceremony

---

Location Room 1,2,3 (3F)  
Date & Time September 17 (Sat) 16:15

## Information for Speakers

### Preview Room

---

The preview room is equipped with PCs that have identical configurations to the ones in the session rooms so that the presenting authors can upload and review the presentation files ahead of their session. Please note that all presenters must stop by the preview room to check and upload their presentation files a day before their presentation or at least 4 hours in advance before the session begins.

#### · Place

Park Studio (5F)

#### · Operating Hours

September 15 (Thu) 11:30-17:00

September 16 (Fri) - September 17 (Sat) 07:30-18:00



## Moderated Poster Presentation & Poster Exhibition Guidelines

### Moderated Poster Presentation

---

Each presenter will be given 8 minutes. Presenters will share their perspectives and recent advancements with the displayed posters for 5 minutes. When the presentation ends, a Q&A session for participants with panels and presenters will follow for 3 minutes. The presentation will be reviewed by a chairperson and 2 panels.

**Date & Time** September 16 (Fri) 15:15-15:55  
September 17 (Sat) 13:35-14:15

**Place** Poster Hall (6F)

### Affixation & Removal

---

**Date & Time** September 15 (Thu) - September 17 (Sat)

**Place** Poster Hall (6F)

**Affixation** September 15 (Thu) 10:00-

**Removal** September 17 (Sat) 17:00-18:00

### Size

---

**Poster Panel Size** W250 x H100 cm

**Paper Size** A0 (W84.1 x H118.9 cm)

### Regulations

---

- Every poster should be affixed to the designated panel according to the assigned poster number notified in advance.
- Posters should be readable by viewers from 1.5 meters away. The poster title, author(s)'s name(s), and affiliation(s) should appear on the top. The message should be clear and understandable without an oral explanation.
- Posters should be able to show the main content or the main results of the research.
- 3M Double-sided tapes and adhesive tapes will be available to attach your poster to the panel. (The tapes will be provided on the site.)
- All presenters should remove posters at the removal time. Otherwise, the remaining posters will be removed by staff without notice and the organizing committee will not take responsibility for any damages or losses of the posters.

## Congress Information

### Stamp Tour Event

---

Participants can collect stamps on the event coupon received from the registration desk by visiting our Platinum, Gold, Silver, and Bronze sponsors in the exhibition area on each floor. When you complete collecting booth stamps, you can exchange the stamp card with a special gift of ICoLA 2022.



Mini Suitcase



Starbucks e-Gift Card

1. All Platinum and Gold booths require full stamps.
2. More than 5 stamps are required from the other sponsors.

- \* One gift is to one person in all lucky draw events
- \* The event may end early when the gifts are out of stock.
- \* A ticket will be provided per person and it cannot be re-issued in case of loss.

Date & Time September 15 (Thu) - September 17 (Sat) 16:00

Place Exhibition booth 3F, 5F, 6F

Place for Gift Presentation Secretariat (5F)

### Lucky Draw Event

---

To make things much more interesting this year, ICoLA 2022 will be having lucky draw events during the welcome reception, the breakfast symposiums, and the closing & award ceremony. There are lots of exciting prizes to be given away. You could very well be one of our lucky winners by submitting your lucky tickets given with your name badges.

### Breakfast Symposium 1-4

After collecting lucky tickets from all attendees for breakfast symposiums, winners will be announced through a raffle by the chairpersons of each session before the end.

Location Room 1,2 (3F)

Date & Time September 16 (Fri) 08:00-09:00 / September 17 (Sat) 08:00-09:00



Dyson Airwrap



LG Robot Cleaner



Starbucks Gift Card

### Welcome Reception

The lucky drawing will be held on the spot.

Location Room 3 (3F)

Date & Time September 15 (Thu) 17:10-



Bose NC 700  
Headphones



Marshall Bluetooth  
Speaker



Braun Electric Shaver



Starbucks Gift Card

### Closing & Award Ceremony

The lucky drawing will be held on the spot.

Location Room 1,2,3 (3F)

Date & Time September 17 (Sat) 16:15-



iPhone 13 Pro



Bose NC 700 Headphones



Samsung Galaxy Buds

## Information for On-site Attendees

### Registration Desk

---

· Location

Lobby (5F)

· Operating Hours

September 15 (Thu) 11:00–17:00

September 16 (Fri) 07:30–18:00

September 17 (Sat) 07:30–16:00

### Congress Kit

---

All attendees can enjoy the benefit of receiving an abstract book and a program book as a present as well as our specially designed ICoLA 2022 eco-bags.

### Name Badge

---





For security purposes, please wear your name badge at all times within the congress venues to access session rooms.

### Breakfast & Luncheon Symposium








---

Meals will be served in the breakfast and luncheon symposiums. The meal box will be served individually after the lectures in the room.

#### Breakfast Symposium

Session	Date & Time	Place	Sponsors
Breakfast Symposium 1	Sep. 16 (Fri) 08:00-09:00	Room 1 (3F)	 CELLTRION PHARM CELLTRION
Breakfast Symposium 2	Sep. 16 (Fri) 08:00-09:00	Room 2 (3F)	 ORGANON
Breakfast Symposium 3	Sep. 17 (Sat) 08:00-09:00	Room 1 (3F)	 YUHAN
Breakfast Symposium 4	Sep. 17 (Sat) 08:00-09:00	Room 2 (3F)	 JW Pharmaceutical

## Luncheon Symposium

Session	Date & Time	Place	Sponsors
Luncheon Symposium 1	Sep. 15 (Thu) 12:00-12:50	Room 1 (3F)	 DAEWOONG
Luncheon Symposium 2	Sep. 15 (Thu) 12:00-12:50	Room 2 (3F)	 CKD Pharm.
Luncheon Symposium 3	Sep. 16 (Fri) 12:00-12:50	Room 1 (3F)	 ORGANON
Luncheon Symposium 4	Sep. 16 (Fri) 12:00-12:50	Room 2 (3F)	 JW Pharmaceutical
Luncheon Symposium 5	Sep. 16 (Fri) 12:00-12:50	Room 3 (3F)	 VIATRIS
Luncheon Symposium 6	Sep. 16 (Fri) 12:00-12:50	Room 4 (5F)	 <i>Boehringer Ingelheim Lilly</i>
Luncheon Symposium 7	Sep. 17 (Sat) 12:05-12:55	Room 1 (3F)	 inno.N
Luncheon Symposium 8	Sep. 17 (Sat) 12:05-12:55	Room 2 (3F)	 <i>Global-R&amp;D Leader Hanmi Pharm.</i>
Luncheon Symposium 9	Sep. 17 (Sat) 12:05-12:55	Room 3 (3F)	 AMGEN
Luncheon Symposium 10	Sep. 17 (Sat) 12:05-12:55	Room 4 (5F)	 sanofi

## Coffee Break

Refreshment will be available in the lobby of 3F, 5F, 6F and Exhibition Hall (5F, Park Ballroom 1,2).


## Certificate of Attendance

Participants are able to download and print the certificate of attendance on the ICoLA official website through 'My page' section after the conference.


## Cloak Room and Lost & Found

Participants can store their luggage in the cloakroom located next to the Poster Presentation Room on the 6<sup>th</sup> floor. Should you lose or find anything, please report to the cloakroom or the registration desk for assistance.


## Exhibitions



Booth No.	Grade	Company Name
1~6	Platinum	Organon Korea
7~12		DAEWOONG PHARMACEUTICAL CO.,LTD
13~18		JW Pharmaceutical
19~20	Bronze	Korea United Pharm. INC.
21~24	Gold	Inno.N
25~28		Chong Kun Dang Pharm.
29~32		Viatrix Korea



Booth No.	Grade	Company Name
1	Exhibitor	Novo Nordisk
2~5	Gold	Hanmi Pharmaceutical
6~9		Boehringer Ingelheim Korea / Lilly Korea
10~13		Yuhan Corporation
14~17		Amgen Korea
18~21		Sanofi Aventis Korea
22~25		Celltrion Pharm
26		Exhibitor
27~28	Bronze	Ildong Pharmaceutical Co.,Ltd
29~30		YooYoung Phamaceutical Co., Ltd
31~32		Abbott Korea Ltd.
33~34		Dong-A ST
35~36		Daewon Pharm
37		Exhibitor
38	Handok	
39~41	Silver	AstraZeneca
42~44		LG Chem
45~47		Boryung Pharmaceutical Company
48~50		DIICHI SANKYO Korea



Booth No.	Grade	Company Name
1~2	Bronze	Novartis Korea
3~4		Samjin pharm Co., Ltd
5~6		GC Biopharma
7~8		HANLIM PHARM.CO.LTD.
9~10		Pfizer Korea
11~12		Korea Otsuka Pharmaceutical Co., Ltd.



## Sponsors

### Platinum



### Gold



### Silver



### Bronze



## Useful Information

### Currency and Banking

---

The unit of Korean currency is 'WON' (indicated as ₩). Coin denominations are ₩10, ₩50, ₩100, ₩500. Bank notes are ₩1,000, ₩5,000, ₩10,000, and ₩50,000. Foreign exchange banks and other authorized money exchangers. International credit cards, such as VISA, Master, American Express, Diners Club, and JCB are widely accepted at major hotels, department stores, and restaurants. US\$1 is equivalent to approximately ₩1,200.

### Tax & Tipping

---

Value-added tax is levied on most goods and services at a standard rate of 10% and is included in the retail price. Tipping is not customary in Korea. Sometimes, expensive restaurants and luxury hotels may add a service charge of 10%. Thus, you do not necessarily have to prepare for extra charges since it will be included in the bill.

### Emergency Call

---

- 1339: Medical Emergency
- 119: Emergencies for Fire / Rescue & Hospital Services
- 112: Police
- 129: First Aid Patients

### Electrical Standards

---

The standard electricity supply is 220V AC/60 cycles. Most hotels may provide outlet converters for 110 and 220V. Participants are advised to check with the hotel beforehand.

### Time









---

When indicating Korea Time: Present time (GMT+9)

## Transportation

### By Subway

Airport Railroad Express operates between Incheon International Airport and Gimpo Airport. At Gimpo Airport, you can transfer to subway line 9. You can take AREX at the Airport Transportation Center(B1) at Incheon International Airport.

Route	Traveling Time	Fare	Remarks
 Incheon airport  Gongdeok Station  Yeouido Station	Approx. T2: 78min Approx. T1: 70min	T2: KRW 4,750 T1: KRW 4,150	Take Airport Railroad (AREX) from Incheon airport Terminal 1 or 2 (bound for Gongdeok Station) then Transfer to subway Line #5 at Gongdeok Station (bound for Banghwa station) → take off at Yeouido Station
 Incheon airport  Gimpo Airport  Yeouido Station	Approx. T2: 78min Approx. T1: 70min	T2: KRW 4,550 T1: KRW 4,050	From Gimpo Airport (approximately 18 min) : Take the Subway express line #9 at Gimpo International Airport station Get off at Yeouido station which provides direct access to Conrad Seoul
 Gimpo Airport  Yeouido Station	19min (6line Express) T1: 26min (5line)	KRW 1,350	Yeouido Stn. (exit #3) is 10 min. walking distance away from Hotel

### By Taxi

Taxi (Incheon Airport → Conrad Seoul Hotel)

#### · Address of Conrad Seoul Hotel

10 Gukjegeumyung-ro (Yeouido) Yeongdeungpo-gu, Seoul, 07326, South Korea

Travel Time	Fare	Classifications
50 mins - 1hr	KRW 60,000 (R) / KRW 75,000 (D) *Toll fee included	R: Regular taxi (Yellow, White) D: Deluxe taxi (Black)



**KSoLA**  
The Korean Society of Lipid and Atherosclerosis



# ICoLA 2023

September 14(Thu)- 16(Sat), 2023

*See you on the next  
ICoLA 2023*





## About the journal

The JLA is an official journal of the Korean Society of Lipid and Atherosclerosis. The journal is devoted to the dissemination of knowledge of the mechanisms responsible for lipid metabolism and atherosclerosis and enhance insight into prevention, treatment, and ultimate cure for cardiovascular diseases. The JLA covers basic, translational, and clinical research of lipid and atherosclerosis. The JLA also encourages articles on broad aspects of vascular biology, thrombosis, metabolism, nutrition, or cardiovascular health. Only manuscripts written in English are accepted. This journal includes review article, editorial, original article, brief report, opinion, and letter to the editor.



**KSoLA**  
The Korean Society of Lipid and Atherosclerosis

## Submit your manuscript



We cordially invite you to submit your papers to JLA. The Journal is published on the official website of the JLA (<https://e-jla.org/>), and you can submit your work through the online submission system (<https://www.editorialmanager.com/jla/>).

<https://www.editorialmanager.com/jla/default1.aspx>

## Recent articles



Check out our recently published articles.

<https://www.e-jla.org/index.php>

## Open access



JLA follows the Open Access Journal policy.

## No submission fee



No author's submission fee or other publication-related fee since all article processing costs is supported by KSoLA.

## JLA video clip



<https://www.youtube.com/channel/UCScS4S1p-kUMa0XCygs0DJA/videos>



효과를 높여보세요  
당뇨병 걱정없이, 약효까지 강력하게!

강력한 이상지질혈증 솔루션  
**리바로젯®**

- |            |  |
|------------|--|
| <b>효과성</b> | • 복용 후 50% 이상 LDL-C 감소효과 입증 <sup>1)</sup><br>• 저 중등위험군은 물론, 고위험군 이상으로 넓어진 치료범위 <sup>2)</sup> |
| <b>안전성</b> | • 당뇨병 안전성을 공인 받은 유일한 스타틴 <sup>3)</sup><br>• 32개국 당뇨병 안전성 공인 <sup>3)</sup>                    |



1), 2) 리바로젯 36상 허가일상 결과 3) 32개 국가 현황 • 유럽(37개국) • 영국, 독일, 프랑스, 스페인, 이탈리아, 핀란드, 네덜란드, 스웨덴, 오스트리아, 아일랜드, 포르투갈, 그리스, 노르웨이 • 동유럽(26개국) • 러시아, 폴란드, 우크라이나, 조지아, 아르메니아 • 동아시아(57개국) • 싱가포르, 대만, 인도네시아, 말레이시아, 카자흐스탄, • 동남아시아(11개국) • 사우디아라비아, UAE, 쿠웨이트, 카타르, 요르단, 오만, 레바논, 바레인, • 아프리카(17개국) • 모로코

# First and only<sup>1,2,\*†</sup>

아토르바스타틴과 **유일한 오리지널 에제티미브 복합제**

**아토젯®**으로 고지혈증 환자의  
치료를 시작해주세요.<sup>1,2</sup>



\* 2021년 10월 기준  
† 아토젯은 상용과 처방기준에 따른 고지혈증 환자에 치료 가능합니다. 아토젯은 오리지널 에제티미브 복합제인 아토르바스타틴/에제티미브 복합제입니다.  
1) 아토젯은 상용과 처방기준에 따른 고지혈증 환자에 치료 가능합니다. 아토젯은 오리지널 에제티미브 복합제인 아토르바스타틴/에제티미브 복합제입니다.  
2) 아토젯은 상용과 처방기준에 따른 고지혈증 환자에 치료 가능합니다. 아토젯은 오리지널 에제티미브 복합제인 아토르바스타틴/에제티미브 복합제입니다.  
3) 아토젯은 상용과 처방기준에 따른 고지혈증 환자에 치료 가능합니다. 아토젯은 오리지널 에제티미브 복합제인 아토르바스타틴/에제티미브 복합제입니다.

**Atozet®**  
(ezetimibe and atorvastatin, MSD)